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resumo 
 
 
A poliadenilação alternativa (APA) é uma etapa de 
processamento de pre-mRNA em que isoformas alternativas de 
mRNA são formadas com base na escolha de um sinal de 
poliadenilação (pA) sobre o outro. Quando confinada à Região 3’ 
não-Traduzida (3’ UTR), a APA gera mRNAs que variam somente 
no comprimento das suas 3’ UTRs (3’UTR-APA). Vários estudos 
têm demonstrado o papel da APA na regulação da expressão 
genética. Nos mamíferos, cerca de 70% de genes são sujeitos a 
APA, aumentando substancialmente a diversidade do 
transcriptoma. APA é relevante tanto em processos fisiológicos 
como patológicos, modulando a estabilidade, localização e 
eficiência da tradução dos transcritos. Trabalhos anteriores do 
grupo demonstraram que o gene Myeloid Cell Leukemia 1 (MCL1) 
tem dois sinais de poliadenilação ativos em células T humanas, 
denominados pA1 e pA2, e que a isoforma pA2 é susceptível à 
regulação pós-transcripcional pelo miR-17 no citoplasma. O 
produto proteico comum às duas isoformas de APA – Mcl-1, é um 
membro anti-apoptótico da família Bcl-2, crucial tanto no câncro 
como na sobrevivência das células T. Um dos objectivos desta 
dissertação consistiu em abordar a influência das duas isoformas 
de APA de MCL1 na localização subcelular de Mcl-1 e em 
verificar se o miR-17 tem um impacto no seu nível de produção 
proteica. Deste modo, os seguintes construtos de expressão 
contendo a sequência codificante de MCL1 (CDS), seguida pela 
sequência da 3’ UTR curta ou longa, foram transfetados em 
células HeLa; pEGFP MCL1 CDS pA1, pEGFP MCL1 CDS pA2 e 
MCL1 CDS pA2∆miR17, e a localização de Mcl-1 foi verificada 
através da microscopia confocal. Pretendíamos ainda otimizar o 
método da deleção dos sinais pA em células difíceis de transfetar 
(Jurkat E6.1), através do uso de construtos CRISPR/Cas9 do tipo 
all-in-one e transdução lentiviral. Para além de planear a criação 
de linhas com um dos sinais pA de MCL1 deletado: MCL1∆pA1 e 
MCL1∆pA2, respectivamente, o nosso objectivo consistiu em criar 
linhas estáveis knock-out (KO) para ambos alelos em dois genes 
envolvidos no processamento de RNA: INTS9 e CPSF1, para 
estudar a sua função na APA e na expressão de MCL1. Os 
ensaios de localização mostraram que Mcl-1 derivado da 
isoforma pA1 é predominantemente expresso na mitocôndria, 
enquanto Mcl-1 derivado da isoforma pA2 tem uma localização 
ubíqua. Além disso, a quantificação da intensidade de EGFP 
mostrou que a isoforma pA1 produz ~ 3 vezes mais proteína que 
a pA2 e que o miR-17 não é responsável pela baixa expressão de 
Mcl-1. Por outro lado, a genotipagem das populações de E6.1 
submetidas a CRISPR/Cas9 revelou deleções em alelos de 
quase todas as condições. De seguida, a heterozigotia foi 
detectada em clones isolados por single-cell sorting. Em 
conclusão, os estudos de localização provam que a regulação da 
expressão genética mediada pela 3’ UTR modula tanto o destino 
como a distribuição subcelular proteica. As abordagens 
CRISPR/Cas9 foram bem-sucedidas, contudo, a homozigotia 
ainda está por alcançar, para permitir a realização de ensaios 
funcionais. Em suma, estes resultados ajudam a esclarecer a 
regulação de isoformas de mRNA derivadas de 3’ UTR-APA de 
MCL1, proporcionando-nos oportunidades para aprofundar o 
conhecimento sobre os mecanismos e os fatores moleculares 
subjacentes. 
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abstract 
 
Alternative polyadenylation (APA) is a pre-mRNA processing step 
in which mRNA isoforms with alternative 3’ ends are formed 
based on the choice of one polyadenylation (pA) signal over the 
other. When confined to the 3’ Untranslated Region (3’ UTR), APA 
generates mRNAs varying only in the length of their 3’ UTRs 
(3’UTR-APA). Various studies have demonstrated a role for APA 
in regulating about 70% of mammalian genes, increasing 
immensely the transcriptome diversity. APA is relevant in both 
physiological and pathological processes, primarily by modulating 
transcripts stability, localization and translational efficiency. From 
our group previous work, it was shown that the Myeloid Cell 
Leukemia 1 (MCL1) gene has two active pA signals in human T 
cells that were named pA1 and pA2 and that the pA2 isoform is 
susceptible to post-transcriptional regulation by miR-17 in the 
cytoplasm. The APA isoforms common protein product – Mcl-1, is 
an anti-apoptotic member of the Bcl-2 protein family, crucial in 
both cancer and T cell survival. One of the aims of this thesis 
consisted in assessing the influence of the two MCL1 APA 
isoforms on subcellular distribution of Mcl-1 and verify if miR-17 
has an impact on Mcl-1 protein production. In order to do so, the 
following expression constructs featuring MCL1 coding sequence 
(CDS) followed by either the short or the long 3’ UTR sequence 
were transfected in HeLa cells; pEGFP MCL1 CDS pA1, pEGFP 
MCL1 CDS pA2 and MCL1 CDS pA2∆miR17, and Mcl-1 
localization was verified by live-cell confocal microscopy. In 
addition, we aimed to optimize a method for pA signal deletion in 
difficult to transfect cells (Jurkat E6.1), by using all-in-one 
CRISPR/Cas9 constructs and lentiviral transduction. Aside from 
planning to generate MCL1 lacking either the proximal 
(MCL1∆pA1) or the distal (MCL1∆pA2) signal, it was our objective 
to generate stable E6.1 double-allele knock-outs (KO) for two 
RNA processing-involved genes: INTS9 and CPSF1 and assess 
their effect on MCL1 APA. The localization assays showed that 
the pA1 isoform-derived Mcl-1 was predominantly expressed in 
the mitochondria while the pA2/ pA2∆miR17 isoforms-derived Mcl-
1 had a ubiquitous localization. Furthermore, the quantification of 
EGFP intensity showed that the pA1 isoform produced ~3-fold 
more protein than pA2, and that miR-17 was not responsible for 
pA2 isoform-derived Mcl-1 low expression. On the other hand, 
genotyping of CRISPR/Cas9-subjected bulk E6.1 populations has 
rendered deletion-positive alleles in almost all conditions. Then, 
heterozygosity was detected in single-cell sorting isolated clones. 
In conclusion, the localization studies prove that the 3’ UTR-
mediated regulation of gene expression reaches into protein fate 
modulation, like subcellular distribution. The CRISPR/Cas9 
approaches have been successful, but homozygosity is yet to be 
reached, to allow conducting functional assays. Overall, these 
results shed light on MCL1 3’ UTR-APA-derived mRNA isoforms 
regulation, providing us with opportunities to delve deeper into its 
subjacent mechanisms and molecular players. 
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Introduction 
Gene Expression  
Gene expression consists in the conversion of the information encoded by a gene 
into a functional gene product. The latter can either be a protein – expressed by structural 
genes through the processes of transcription and translation, or a functional RNA (e.g. 
ribosomal RNA (rRNA), small nuclear RNA (snRNA), micro RNAs (miRNA) – expressed 
by non-coding genes1.  
According to the central dogma of molecular biology2, the information flows from 
DNA to RNA (transcription) and finally to protein (translation). However, this simple two-
step model does not reflect the complexity and interdependency of the processes involved 
in gene expression, especially in eukaryotic cells, which, for instance, feature 
transcriptional auto-regulatory feedback loops3. Gene expression is subjected to regulation 
at many levels; starting in the nucleus with a panoply of epigenetic modifications in the 
chromatin (e.g. chromatin remodeling, histone marks) or in DNA (e.g. base methylation)4. 
Furthermore, gene expression is highly regulated during mRNA synthesis, which in 
eukaryotes is a dynamic process that occurs in the nucleus and requires a tight connection 
between transcription, chromatin remodeling and co-transcriptional processing of the 
precursor (pre-) mRNA5–7– an unfinished product of transcription containing both exons 
and introns. The pre-mRNA processing includes: 5' capping (methylated guanosine – Gm7, 
addition to the 5’end), splicing (intron excision and exon ligation), 3’ end formation and 
also editing (e.g. base modification8)5,7. The orchestration of these distinct processes is 
performed by the RNA polymerase II (RNAPII) through its Carboxy-Terminal Domain 
(CTD), which undergoes differential phosphorylation (among other types of post-
translational modifications – PTM) throughout transcription initiation, elongation and 
termination. The RNAPII CTD allows coupling transcription and pre-mRNA processing in 
time and space: firstly, processing reactions are modulated by the kinetics/ transcriptional 
rate of RNAPII, and secondly, CTD acts as a platform to recruit several transcriptional and 
processing factors, as well as those involved in the packaging of the primary transcript into 
messenger RNA Nuclear Particles (mRNPs)5–7.  
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Polyadenylation 
Polyadenylation is a pre-mRNA 3’ end processing step, which consists in the 
addition of a stretch of adenosine monophosphates not encoded by the gene – a 
polyadenylate [poly(A)] tail, by the poly(A) polymerase (PAP). This occurs after 
endonucleolytic cleavage of the nascent transcript, determined by the binding of 
polyadenylation factors9–13 to the cleavage/ polyadenylation site (PAS). As previously 
reviewed, some of the factors involved in the formation of the pre-mRNAs 3' ends also 
associate with transcription initiation and other events of processing5–7,14–18, like alternative 
splicing (AS)19–21. Furthermore, several polyadenylation factors are involved in setting up 
appropriate chromatin architecture to aid in efficient transcriptional elongation and 
termination22,23. 
The pA tail is present at the 3' end of almost all eukaryotic mRNAs (except histone 
mRNAs24) and some long non-coding RNAs, influencing all levels of mRNA metabolism 
up to maturation, such as: splicing, mRNA export to the cytoplasm, cytoplasmic mRNA 
stability, translational efficiency and storage25–30. The length of the poly(A) tail varies 
greatly between species (e.g. 250-300 adenines in humans versus 70-80 adenines in 
yeasts)25.  
There are several cis-elements involved in the polyadenylation process, comprising 
a series of regulatory sequences located mostly in the terminal end of the 3’ Untranslated 
Region (3’ UTR), some of which act in concert to determine the choice of a 
polyadenylation signal – pA signal. The canonical pA signal sequence AAUAAA11,31, 
which is the strongest in polyadenylation efficiency, is highly conserved, being found in 
the vicinity of  ~53–58% of human PAS32–34. This consensus hexamer acts as a signal for 
polyadenylation as well as for transcriptional termination16,17,35, being located 10-30 
nucleotides (nt) upstream of the actual PAS – preferably, a CA dinucleotide. Apart from 
the canonical sequence, the pA signal exists in more than ten weaker variants10,12,31. 
A classical mammalian pA signal associates with another core cis-element; a G/U 
or U-rich Downstream Sequence Element (DSE)11,36, which may be of supreme importance 
in the presence of some pA signals of the non-canonical type37. Given that database 
analyses have shown that up to 30% of polyadenylation events do not require the 
consensus AAUAAA hexamer and ∼20% of human PASs are not associated to a U- or 
GU-rich DSE32,38,39, auxiliary elements are often present upstream of the PAS – Auxiliary 
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Upstream Elements (AUEs). Among the latter, the involvement of U-rich Upstream 
Sequence Elements (USEs) in polyadenylation is the best characterized, being exemplified 
by Complement C240 and COX-241.  
Furthermore, additional auxiliary cis-elements, localized upstream and downstream 
of the pA signal, are sometimes needed to enhance the polyadenylation of weak pA signals 
and may help determine the PAS when there are multiple ones36.  
The basal polyadenylation machinery consists of 4 protein complexes : Cleavage 
and Polyadenylation Specificity Factor (CPSF), Cleavage Stimulating Factor (CstF), 
Cleavage Factor  Im and IIm (CFIm and CFIIm)42. CPSF is composed by the following 
subunits: CPSF-30/CPSF4, CPSF-73/CPSF3, CPSF-100/CPSF2, CPSF-160/CPSF1, 
Fip1/FIP1L1 and WDC146/WDR3342,43. The polyadenylation machinery also includes 
other proteins, such as PAP, symplekin, PABPN (Poly(A)-Binding Protein Nuclear) and 
RNAPII42. 
The CPSF complex binds to the CTD through its -160 kDa subunit and to the 
AAUAAA hexamer through the WDR33 and CPSF30 kDa subunits44, as was recently 
shown by structural studies made by Sun and colleagues44. It acts in concert with the CstF 
complex, which binds the GU-rich DSEs through its CstF-64 subunit10, thus promoting 
pre-mRNA cleavage between these two cis-acting elements. Additionally, the cleavage 
factors I and II (CFIm and CFIIm) bind upstream of the AAUAAA and are essential for the 
cleavage step. The PAP is then recruited to this processing complex, resulting in 3’ end 
polyadenylation of the cleaved product. Then, in most eukaryotic species, the poly(A) tails 
are bound by two important poly(A)-binding proteins (PABPs): PABPN1 in the nucleus 
and PABPC1 in the cytoplasm, respectively45.  
Regarding transcriptional termination, it is thought that there are multiple processes 
that can contribute to it, with different types predominating at different genes. For 
polyadenylated mRNAs, transcription termination often requires the polyadenylation 
signal, but not the cleavage site, with cleavage-independent and torpedo-style (exonuclease 
promoted)  models of termination being able to occur in parallel46. The only crucial factor 
needed for efficient termination is the necessity of RNAPII to undergo a displacing 
conformational change and disengage from the DNA47.  
 
4 
 
Alternative Polyadenylation 
It is now well-established that alternative pre-mRNA processing exerts a very 
crucial role in modulating gene expression5–7, mainly because of its ability to generate 
multiple transcripts harboring different coding sequences. This may be achieved by 
alternative splicing and/or alternative polyadenylation  (APA), when alternative pA signals 
occur in the intronic or coding regions – internal pA signals (Fig. 1, upper panel), also 
called CR-APA. These two types of alternative processing give rise to protein isoforms 
with different functions, which may even be antagonistic when compared to the full-length 
(FL) isoforms. This is the case of the receptor tyrosine kinase (FL) and its truncated 
soluble decoy alternative protein isoform with a dominant-negative effect, which comes to 
lack the anchoring domain upon activation of an intronic pA signal48. 
However, even if alternative transcripts possess the same coding sequence, they can 
still vary in the length of their 3’ UTR, due to APA confined to this region (Fig. 1, lower 
panel), also named 3’ UTR-APA. As insightfully stated by Hughes, untranslated regions 
are “not just the ends, but the means to an end”49, because the majority of downstream 
effects on the transcript’s journey are largely dependent on sequences contained in this 
region. Those effects include: nuclear export, cytoplasmic localization and translation 
efficiency along with stability26,50 (Fig. 3, right panel). These processes are mediated by a 
variable repertoire of RNA Binding Proteins (RBPs), which bind to a range of cis-
regulatory motifs associated with each of these activities, thus serving as adaptors to a 
variety of effector proteins51–53. Notably, a panoply of novel RBPs (such as some of the 
heat shock proteins – HSPA1A, HSP90), lacking conventional RNA Binding Domains 
(RBDs), were recently unveiled54. 
 
Protein-coding genes can harbor two or more pA signals in their sequences and 
thus the 3’ end formation can occur at different – alternative PAS. Different studies have 
demonstrated that 70-80% of the mammalian genes contain alternative pA signals, 
increasing immensely the potential for transcriptome diversity55,56. 
The direct role of RNAPII elongation kinetics in the selection of PASs in the 3' 
UTR of genes was demonstrated in vivo using D. melanogaster as a model organism57,58. 
Hypothetically, the slower the elongation rate of RNAPII, the longer the exposure of the 
proximal PAS to cleavage and polyadenylation factors, favoring its selection by the 3’ end 
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processing machinery over the distal one, according to the  “first come, first served” 
model12,13. Hence, the proximal PASs possess an intrinsic advantage over the distal ones. 
However, in genes subjected to APA regulation, the respective distal PASs may 
compensate for their unfavorable position relative to the proximal PASs by being 
associated to cis-elements of a more canonical type, including the AAUAAA consensus 
hexamer and the U/ GU-rich DSE10,31,59.   
Three prime end processing factors relative concentrations influence greatly the 
APA outcome13,59. Thus, the higher the concentration of a particular polyadenylation 
factor, the greater the probability that it will bind all of its available cis-elements, while at 
lower concentration only the ones presenting a higher affinity will be bound10. The first 
study that confirmed this hypothesis was focused on the APA modulation of the IgM heavy 
chain pre-mRNA by the CstF-64 levels during B cell differentiation60. Afterwards, and in 
concordance with the previous hypothesis, bioinformatics data showed that the usage of 
alternative pA signals is indeed biased in different tissues, suggesting a reliance on both 
trans-acting factors and cis-regulatory elements61.  
In the light of the given facts, it can be concluded that even small changes in the 
concentration of any of the factors upon cell transformation and differentiation, will affect 
the processing of the 3' end and change 3' UTR ratios, thus ultimately impacting gene 
expression9,62–64. 
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Figure 1 – Alternative Polyadenylation in the coding region (CR) – upper panel, and in the 3’ Untranslated 
Region – lower panel. CR-APA gives rise to different protein isoforms whereas UTR-APA-derived mRNA 
isoforms encode the same protein.  Source: Di Giammartino et al., 201110. 
 
 
The Role Of The 3’ UTR 
Notably, in humans, the median length of the 3’ UTR of genes subjected to APA is 
of 2,462 nt55,64, harboring many islands of conserved sequences, with a degree of 
conservation similar to that of coding regions, and these islands often contain binding sites 
for miRNAs or RBPs65,66. 
It was shown that 3’ UTRs play regulatory roles that are unrelated to the encoded 
protein, with them being able to act as long noncoding RNAs (e.g. the 3’ UTR of the VegT 
mRNA regulates anchoring of vegetal pole–associated transcripts in Xenopus oocytes67). 
On the other hand, the expression of 3’ UTRs can be independent from the coding 
regions. Through analysis of CAGE libraries of human, mouse, and fly tissues, it was 
found that a large number of 3’ UTRs contained 5’ caps and that their expression was often 
much higher than that of coding regions, sometimes reaching more than a 20-fold 
difference68,69. 
The 3’ UTR-APA mRNA isoforms may be differentially localized in the cell, thus 
exerting different cellular functions in compliance with spatiotemporal patterns of protein 
expression and available molecular interactors. That is the case for the Brain-Derived 
Neurotrophic Factor (BDNF), with the short isoform being restricted to the soma and the 
long isoform being targeted to dendrites and  involved in spine morphology and synaptic 
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plasticity, in hippocampal neurons70. In addition, our group has demonstrated that the 
longest RAC1 3′ UTR is necessary for its transcript targeting to the neurites, and for the 
subsequent neurite outgrowth in cortical neurons71.  
Apart from mRNA localization, 3’ UTR can also be responsible for localizing the 
proteins themselves, through an independent mechanism. As recently discovered by Mayr 
and colleagues52, the 3’ UTR can modulate differential protein localization due to the 
establishment of distinct Protein-Protein Interactions (PPI) on the nascent peptide through 
specific recruitment of protein partners by the 3’ UTR of APA-derived mRNA isoforms. 
Such is the case for the CD47 protein, which when produced from the long 3’ UTR APA 
mRNA isoform, localizes to the membrane (Fig. 2), whereas when produced from the short 
APA isoform, it localizes mainly to the endoplasmic reticulum52. Also, as one isoform 
establishes a particular PPI at the translational level and the other does not, the domains of 
the latter are available to other interactions. Thus, different 3’ UTR APA-scenarios can 
ultimately lead to totally different functional outcomes (e.g. apoptosis induction versus 
survival52), even if the proteins bear an identical amino acid sequence.    
 
Figure 2 The 3' UTR- dependent protein localization model of CD47.In the nucleus, only the long 3’ UTR 
APA-derived CD47 isoform recruits HuR, which then recruits SET. SET, by its turn, is transferred onto the 
nascent protein upon translation and then targets the protein complex to the plasma membrane when 
associated with RAC1. Source: Mayr and Berkovits (2015)52. 
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APA In Physiological Context And In Disease 
As the polyadenylation is strongly regulated by cis- and trans-acting factors, their 
deregulation can affect gene expression and, ultimately, lead to disease.  
Studies have shown that APA is under intense regulation during embryonic 
development63,72, presenting a global 3’ UTR lengthening pattern63, which provides a 
larger regulatory landscape associated with coordinating differentiation and 
morphogenesis. On the other hand, in cases of response to pathophysiological cues (e.g. 
HSP70.3 APA in ischemia/ reperfusion injury73), in oncogenic transformation62,74, as well 
as in cell proliferation75 , there is often observed a phenomenon of global 3’ UTR 
shortening.  In the light of these studies, the shorter APA isoforms were associated with a 
higher degree of dedifferentiation/proliferation and vice-versa75. However, one should be 
mindful that the 3’ UTR “shortening” phenomenon, which would be a nuclear co-
transcriptional event due to an increased choice of the proximal PAS, may not happen in 
all the cases. Instead, a differential expression of 3’ UTR APA-derived long and short 
mRNA isoforms may occur at a post-transcriptional level, being modulated mostly by 
nuclear retention of the longer isoform or by miRNAs or RBPs in the cytoplasm76.  
The consensus explanation for the relationship of shorter APA isoforms with cell 
proliferation was formulated on the basis that shorter 3' UTRs confer greater stability 
(which depends on the ratio of synthesis vs decay rates) to the transcripts, partly due to the 
lack of specific sequences within the truncated 3' UTR, targeted by RBPs and miRNAs that 
act in a repressive way on mRNA expression75. Thus, shorter isoforms were associated 
with a more efficient protein production62,75, as was recently demonstrated by our group for 
the short CD5 APA-derived isoform, upregulated upon human T-cell activation77. 
However, genome-wide studies revealed that global 3’ UTR shortening upon the shift in 
PAS usage is not always accompanied by increased mRNA stability78 and/ or protein 
production78,79. These observations highlight the importance of analyzing individual genes 
in the proper cellular context, to assess the functional relevance of APA isoforms. For 
instance, the polo gene in Drosophila is a case in which the efficient translation of the 
longer isoform occurs, with the deletion of the distal pA signal in vivo resulting in the 
production of only short isoforms and thus leading to aberrant patterns associated with 
Drosophila morphogenesis57 due to the deficit of Polo protein. 
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Abnormalities in the 3' end processing mechanism are associated with various 
hematological, oncological, immunological and neurological diseases, thoroughly 
reviewed by Curinha and colleagues in 201480,  which highlights the importance of  
understanding the APA mechanism and its modulation by cis- and trans-factors.  
For instance, in α and β-thalassemia, abnormalities in polyadenylation and 
transcriptional termination occur due to point mutations in the proximal canonical pA 
signal (AAUAAA AAUAAG for α- and AAUAAA  AACAAA for β- thalassemia), 
which leads to 3’ UTR lengthening, insufficient transcript and hence, low α/ β-globin 
synthesis81,82. In trombophilia, on the other hand, there is a point mutation, which 
transforms a normal weak PAS variant into a strong one (CG  CA). This leads to a more 
efficient transcriptional termination due to an increased usage of the PAS and hence to 
thrombin mRNA and protein overexpression, with deleterious effects13,83. 
In cancer, gene upregulation is often observed, which can be due to regulatory 
escape caused by 3’ UTR shortening upon increased usage of the proximal PAS [e.g. 
proto- oncogene insulin-like growth factor 2 mRNA binding protein 1 (IMP-1)84,85]. 
Importantly, as recently found in cancer, the proximal PAS shift in oncogenes often 
disrupts the whole competitive endogenous RNAs (ceRNAs) network, transcripts which 
act as sponges for miRNAs of their mRNA counterparts, because the oncogenes share 
binding sites for these miRNAs with tumor suppressor genes. As a result, not only 
oncogene overexpression is achieved, but also tumor suppressor genes downregulation, as 
they become more prone to miRNAs regulation86.  
In Alzheimer, in contrast, there is observed a 3’ UTR lengthening phenomenon, 
due to a more frequent usage of the distal PAS upon expression of the cyclooxygenase 2 
gene (COX-2). This results in COX-2 transcript downregulation, caused by the targeting of 
regulatory sequences in the long 3’ UTR isoform, thus leading to disease onset87.  
In conclusion, APA is continuously being demonstrated to play universal and 
relevant roles both at physiological and pathological level, with global APA regulation (3´ 
UTR shortening or lengthening) being involved in the ever-increasing number of 
biological and pathological processes (Fig. 3). 
However, “omics” data originated by applying numerous genome-wide high-
throughput technologies existent to date88 need to be combined with focused candidate 
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gene approaches, in order to unveil the biological function of given genes and also their 
regulation mechanisms, which when thrown off balance underlie pathological conditions. 
 
Figure 3 – Functions of Alternative polyadenylation in the 3’ Untranslated Region. Source: Chen et al., 
(2017)88. 
 
 
Myeloid Cell Leukemia 1 (MCL1)  
Myeloid cell leukemia 1 (MCL1) gene was first shown to be overexpressed in a 
human myeloblastic leukemia cell line (ML-1 cells), at an early differentiation stage, by 
Kozopas and colleagues in 199389. Its protein product induced myeloid leukemia cell 
differentiation protein (Mcl-1)  is associated with poor prognosis in various cancers, such 
as ovarian carcinoma90 and certain subtypes of breast cancer, including its aggressive 
triple-negative form91, being thus a relevant target for a range of chemotherapeutic 
agents92,93.   
Mcl-1 is an anti-apoptotic member of the Bcl2 protein family and is unique in that it is 
crucial for embryonic implantation and early development94,95, as well as for the survival 
of multiple cell lineages in the adult96. As shown from the analysis of different conditional 
knock-out (KO) mice, Mcl-1 promotes survival in many cell types including; 
hematopoietic stem cells97,98, lymphocytes99–101, neutrophils102,103,  immunoglobulin-
secreting plasma cells104, neural precursor cells105,106, cardiomyocytes107 , hepatocytes108, 
pancreatic β - cells109 and thymic epithelial cells (TEC)110 
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Mcl-1 in T-cells Development And Pathophysiology 
Thymus-dependent (T) lymphocytes (T cells) are cells of the hematopoietic lineage 
that develop in the bone marrow from a common lymphoid progenitor with other 
lymphocytes, such as B lymphocytes and natural killer cells. T cells are distinct from their 
lymphocyte counterparts by featuring cell surface T-cell receptors (TCRs), which 
recognize antigen peptide fragments bound to major histocompatibility complex (MHC) 
molecules on the surface of antigen-presenting cells111–113. In this fashion, T-cells are 
activated, driving antigen-specific immune responses. Thus, the majority of T lymphocytes 
are master regulators of adaptive cell-mediated immunity, with the exception of γδ T 
cells114,115, which present tissue-specific invariant or restricted TCRs, thus displaying 
innate-like properties. 
The name “T cells” arose because, unlike other lymphocyte lineages, even though 
their precursor cells are generated in the bone marrow, they migrate and colonize the 
thymus, giving rise to large numbers of thymocytes from which T-cells complete their 
maturation, through interactions with the thymic stroma110–113. In the thymus, developing 
thymocytes go through a series of distinct phases, marked by changes in the locus 
rearrangement and expression of the TCR (conventional α:β or γ:δ type) gene as well as 
differential expression of cell-surface proteins; such as the CD3 complex and the co-
receptor proteins – CD4 and CD8. Thus, thymocytes firstly differentiate sequentially 
through four “CD4-, CD8-” double-negative stages (DN1, DN2, DN3, DN4), into double-
positive (DP) “CD4+, CD8+” cells. They also undergo negative selection during and after 
the double-positive stage, which consists in eliminating those cells that respond to self-
antigens. Then, DP thymocytes stop expressing either one or the other of the two co-
receptor molecules, bifurcating to ultimately differentiate into single positive (SP) – 
“CD4+,CD8-”  or “ CD8+,CD4-” thymocytes.  
Afterwards, SP thymocytes exit the thymus and enter the peripheral blood. There, 
they attain functionality following activation and clonal proliferation.112 Thus, they 
differentiate from naïve T cells into effector T cells – CD8+ cytotoxic T cells and CD4+ 
helper T cells. While cytotoxic T cells kill infected cells, helper T cells assist in the 
activation of macrophages, B cells, and cytotoxic T cells.112  
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In order to determine the role of Mcl-1 in T cell development and function, a 
variety of studies have been carried out. For example, Opferman and colleagues97 and 
Dzhagalov and colleagues100 showed that T lymphocytes depend on Mcl-1 throughout all 
of their developmental stages, for survival and maintenance. These authors showed that in 
the Mcl-1 null mice, DN2 thymocytes presented increased apoptosis whereas DN3 
thymocytes showed arrested development, with a decrease in the overall numbers of both 
DP and SP thymocytes. Moreover, they demonstrated that Mcl-1 has a role in maintaining 
the local population of mature T lymphocytes, since the deficit in Mcl-1 led to the 
depletion of T cells from the spleen97.  
Dzhagalov and colleagues100 confirmed that the MCL1 knock-out resulted in the 
DN3 arrest, as well as in the decrease in the number of SP thymocytes.                                                                                                                                                                                                                                                                          
In addition, they showed that while in vitro DP thymocytes depend on Mcl-1 for their 
survival, in vivo its importance is diminished due to the involvement of other anti-apoptotic 
members100. However, later on, Pierson and colleagues116 showed in vivo that Mcl-1 was 
critical for T regulatory cell survival, with its loss causing fatal autoimmunity, whereas 
anti-apoptotic proteins Bcl-xL and Bcl-2 were not as important. However, more recently, 
the relevance for T-cells survival was once again shown to rely on the cumulative 
participation and relative levels of various anti-apoptotic proteins rather than just one, both 
in vitro and in vivo117.   
Regarding the Mcl-1 role in activated T cells, Dzhagalov and colleagues100 
demonstrated that in T-cells purified from mice with MCL1 tamoxifen-inducible deletion 
system, activated T lymphocytes had undergone apoptosis upon lack of Mcl-1 expression, 
being thus clearly reliant on this anti-apoptotic protein. In addition, when T cells were 
stimulated with an antibody (Ab) binding the CD3 molecule present on T-cells surface 
(anti-CD3 Ab), a high Mcl-1 up-regulation was observed100. Consequently, it was 
concluded that higher levels of Mcl-1 were needed in T-cells activation, with Mcl-1 being 
important both for the survival and function of activated T cells100. 
 
MCL1 Characterization and Regulation 
The human MCL1 gene locus resides on chromosome 1q21 and comprises 3 
exons118 that encode the anti-apoptotic protein Mcl-1, which is a member of the B cell 
lymphoma-2 (Bcl-2) family118–120. MCL1 promoter harbors various elements, such as sis-
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inducible element (SIE) – at position -87, and cAMP-response element 2 (CRE-2 ) – at -
70121,122, which participate in the transcriptional activation of MCL1. The latter is subjected 
to control by several proteins, among which feature growth factors (e.g. epidermal growth 
factor – EGF123,  vascular endothelial growth factor – VEGF124) and a variety of 
interleukins, namely; IL-3121,  IL-5125, IL-6126,127 and IL-799. These cytokines trigger both 
the Mitogen-Activated Protein Kinase (MAPK) cascade and the phosphatidylinositol 3-
Kinase  – Serine/ Threonine Kinase (PI-3K – Akt) signaling pathway, leading to the 
activation of Janus kinases (JAK1, JAK2) and signal transducers and activators of 
transcription (e.g. STAT3, STAT5), thus ultimately inducing MCL1 expression and 
inhibition of apoptosis128. 
In addition, other transcription factors, such as the purine-rich box binding PU.1129 
and the hypoxia-inducible factor 1-alpha (HIF-1α)130 – on one hand, and the E2 Promoter 
Binding Factor 1 E2F1131 – on the other hand, were also described to up-regulate and 
down-regulate MCL1 transcription, respectively, by binding to its promoter.  
At a co-transcriptional level, MCL1 is subjected to AS, giving rise to three AS-
derived mRNA isoforms,118,119,132 (Fig. 4). The longest, and the predominantly expressed, 
AS isoform (Mcl-1L) is anti-apoptotic (Fig. 4), enhancing cell survival through inhibition 
of apoptosis118,119,132. It codifies for one N-terminal PEST domain– peptide sequence that is 
rich in proline (P), glutamic acid (E), serine (S), and threonine (T), four Bcl-2 Homology 
(BH) motifs, and one C-terminal transmembrane (TM) domain119. 
However, through skipping of exon 2 or through skipping of a portion of exon 1, 
two shortened AS mRNA isoforms are generated; Mcl-1S133 and Mcl-1ES134 (Fig. 4), 
respectively. MCL1S lacks the C-terminal BH2 motif and the TM domain, while Mcl-1ES 
lacks the N-terminal PEST domain and the BH4 motif133,134. Contrary to the full-length 
anti-apoptotic isoform (MCL1L), these two AS-derived isoforms promote apoptosis and 
induce cell death by, on one hand, sequestering the Mcl-1 anti-apoptotic isoform (dominant 
negative effect) and on the other hand, being unable to interact and sequester the pro-
apoptotic Bcl-2 family members119 . 
In addition to AS, mRNA stability/ turnover is critical in regulation of gene 
expression and also for mRNA quality control. Generally, the mRNA decay rate is 
modulated by RBPs bound to its RNA-stabilizing and RNA-destabilizing cis-acting 
elements, commonly located in the 3’ UTR. The 3’ UTRs’ length of the anti-apoptotic 
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BCL2 family members is quite variable (1506 to 5278 nt). The BCL2 family members also 
present significant variation in their respective mRNA half-lives132. 
For MCL1 mRNA, different RBPs bind to its AU-rich elements (ARE) present in 
the 3’ UTR, both stabilizing (by HuR – human antigen R, in glioma135) and destabilizing 
(by tristetraprolin – TTP, in bacterial pathogen-engaged neutrophils136), increasing or 
decreasing gene expression, respectively. In addition, 3’ UTR GU-Rich-Elements (GRE) 
are reported to enhance MCL1 transcript stability through binding to CUGBP2/ CELF2 
(CUG triplet repeat RNA-binding protein 2)137, even though it suppresses protein 
expression, whereas 3’ UTR CU-rich elements bound by PTBP1 (polypyrimidine tract 
binding protein 1) destabilize MCL1 mRNA138. However, besides stability, PTBP1 also 
impacts MCL1 transcript localization, given that PTBP1 knockdown was described to 
enhance MCL1 mRNA enrichment in the cytoplasm relative to the nucleus, thus impacting 
distribution of MCL1 mRNA, in prostate and lung cancer cells138. 
MCL1 is also down-regulated in the cytosol by miRNAs, being miR-29b139 the 
most well-studied. 
Finally, at the level of post-translational regulation, MCL1 is positively regulated 
through the PI-3K – Akt -mammalian target of rapamycin complex 1 (mTORC1) 
pathway140. 
 
 
Mcl-1 In The context of Apoptosis And The BCL-2 Protein Family  
Apoptosis is a programmed form of cell death and occurs under intrinsic (upon 
DNA damage) or extrinsic (through engagement of death receptors at the plasma 
membrane, such as Fas) cellular stress conditions. It largely relies on Mitochondria Outer 
Membrane Permeabilization (MOMP), with a release of the apoptogenic factor cytochrome 
c (cyt c) from the mitochondria, which subsequently triggers a caspase activation cascade, 
and then several downstream processes, such as cell dismantling141,142.  
The mammalian BCL-2 protein family consists of both pro-apoptotic and anti-
apoptotic members, which constantly interplay, dictating cell fate – survival or apoptosis. 
The pro-apoptotic members split into ‘effectors’, which mediate MOMP [e.g BCL-2 
antagonist killer 1 (BAK), BCL-2-associated X protein (BAX)]; direct activators, which 
engage and activate the pro-apoptotic effectors, [e.g. BCL-2 interacting domain death 
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agonist (BID), BCL-2 interacting mediator of cell death (BIM), p53-upregulated modulator 
of apoptosis (PUMA)], and derepressors/ sensitizers, which sequester and inhibit anti-
apoptotic proteins [BCL-2 antagonist of cell death (BAD), BCL-2 interacting killer (BIK), 
BCL-2 modifying factor (BMF), harakiri (HRK) and Noxa]120,143. The anti-apoptotic 
family members [BCL-2, BCL-xL, BCLw, Mcl-1, and BCL-2-related gene A1 (A1)], on 
the other hand, inhibit MOMP, by sequestering pro-apoptotic direct activators and 
effectors, thus antagonizing the direct activator–effector MOMP axes (Fig. 4).  
Homology analyses revealed that effector and anti-apoptotic BCL-2 proteins share 
a high structural homology, namely the four Bcl-2 Homology domains (BH1–4), whose 
globular folds form a hydrophobic cleft termed the BCL-2 core144. However, except 
BID145, both direct activators and derepressors/ sensitizers are BH3-only proteins, lacking 
these globular folds and being intrinsically disordered146. Furthermore, many Bcl-2 family 
members contain a transmembrane (TM) domain at the C-terminus, which allows 
anchoring to the Mitochondrial Outer Membrane, where they exert their function (e.g. 
Mcl-1, Bak).  
The Mcl-1 protein distinguishes from the other Bcl-2 family anti-apoptotic 
members because of its short half-life, due to its extensive post-translational regulation. It 
is a relatively large protein, unlike other anti-apoptotic Bcl-2 members, comprising 350 
amino acids (Fig. 4), with 170–300 residues sharing structural/ functional homology to 
both Bcl-2 and Bcl-XL140. Mcl-1 length is mainly due to its extensive unstructured N-
terminal region, which is not present in other Bcl-2 family members and is involved in 
various post-translational modifications of Mcl-1. Those modulate Mcl-1 turnover and 
activity, providing the protein with the ability to quickly and reversibly respond to 
environmental cues, and thus switching cell fate from survival to apoptosis. 
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Figure 4 – From top to bottom: MCL1 gene, transcript AS-derived isoforms and protein isoforms. Source: 
Cui and Placzek (2018)132. 
 
 
According to the widely accepted unified model of mammalian Bcl-2 protein 
family interactions at the mitochondria120,142,147, anti-apoptotic Mcl-1 blocks MOMP by 
sequestering the pro-apoptotic effector pore-complex-forming Bak, through binding its 
BH3 domain. It may also inhibit direct activator BH3-only proteins; Bim, Puma and tBid, 
depending on cell stress (Fig. 5). On the other hand, Mcl-1 is antagonized by sensitizer 
BH3-only proteins such as Noxa, which displaces Mcl-1 from Bak and Bax (Fig. 5).120,147 
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Figure 5 –  Bcl-2 family members function in apoptosis. Legend: IMM: Inner Mitochondrial Membrane; 
OMM: Mitochondrial Outer Membrane; MOMP: Mitochondria Outer Membrane Permeabilization. Source: 
Moldoveanu et al., (2014)120  
 
 
Mcl-1 Localization And Non-Apoptotic Function 
The PEST region of Mcl-1, whose reversible phosphorylation regulates this protein 
stability, also regulates its subcellular distribution, as shown by mutational studies of the 
residue Ser162, located within this region148. Mutation of Ser162 to the phospho-null 
residue Alanine resulted in predominant nuclear localization, with some cytoplasmic but 
no mitochondrial localization148, the latter shown as prevalent by various studies, being 
where Mcl-1 exerts its anti-apoptotic function when anchored to the OMM148–150. This 
Ser162 mutant Mcl-1 protein isoform also showed a significant decrease in stability and its 
ability to inhibit Bak-induced apoptosis148.  
Both the deletion of the transmembrane domain at the Mcl-1 C-terminus 
(MCL1∆TM) – needed to anchor Mcl-1 to the OMM, and of 79 aa in the N-terminus 
(MCL1∆N79) – bearing a mitochondrial targeting signal, were shown to disrupt Mcl-1 
mitochondrial localization149,150. However, although MCL1∆TM did not co-localize with 
the mitochondrial Translocase of the Outer Membrane 20 (TOM20) transport receptor at 
the mitochondria, MCL1∆N79 co-localized with TOM20 in 15% of the cells. Curiously, 
after the inhibition of protein synthesis, the number of cells with mitochondrial 
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MCL1∆N79 increased over time, suggesting that the cytosolic localization of MCL1∆N79 
was the consequence of a slower rate of import150. 
Also regarding Mcl-1 targeting to mitochondria, a BH3-only pro-apoptotic protein 
Noxa/ PMAIP was shown to enhance it in HeLa cells, by establishing PPI with Mcl-1 in 
the cytosol through the BH3 domain, and hence leading to protein complex co-localization 
to the mitochondria151. Moreover, Noxa was shown to lead to Mcl-1 phosphorylation and 
subsequent ubiquitination upon entry to the mitochondria, thus enhancing Mcl-1 ubiquitin–
proteasome system (UPS)-mediated degradation. 
However, Mcl-1 also carries on other functions at the mitochondria, such as 
regulation of metabolism at the Inner Mitochondrial Membrane (IMM)152,153, shaping of 
mitochondria structure and dynamics (fusion/ fission)153–155 and mitophagy154.  
In addition to its diverse roles at the mitochondria organelle, Mcl-1 was also shown 
to function in the nucleus. In particular, it regulates cell-cycle progression by engaging 
Proliferating Cell Nuclear Antigen (PCNA)156 and  Cyclin-dependent kinase 1 (Cdk1)157 in 
the nucleus, through its proteolytic protein isoform157. Furthermore, Mcl-1 was shown to 
be specifically and timely accumulated in the nucleus in response to DNA damage, through 
interaction with the radiation-inducible immediate-early gene IEX-1, while in the absence 
of the latter, Mcl-1 returned to the cytosol. Both proteins were shown to cooperate to foster 
checkpoint 1 (Chk1) activation and G2 checkpoint arrest upon DNA damage, with loss of 
either protein leading to genomic instability and high sensitivity to genotoxic stress158. 
Finally, also in the nucleus, Mcl-1 was demonstrated to regulate the mesenchymal-
epithelial transition when associated to STAT3159, which is needed upon embryonic 
implantation.  
In conclusion, it is evident that Mcl-1 has diverse functions related to cell survival, 
which is in agreement with the observation of its relevance in so many different cell types 
and tissues.  
 
 
CRISPR/ Cas9 Genome Editing System Overview 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas 
(CRISPR-associated) proteins have been detected in bacteria and archaea for years160, and 
discovered only a decade ago to function as a RNA-based adaptive immune system in 
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prokaryotes, targeting viral genomes for degradation in a sequence-specific manner by the 
means of a RNA-guided DNA endonuclease161.   
Later on, the most studied type II bacterial-only CRISPR/Cas9 system has been 
made into the most efficient and powerful tool for genomic engineering to date162. It is the 
simplest CRISPR/Cas9 system, due to concentrating all of its endonuclease activity in a 
single multidomain protein – Cas9163, (Fig, 6a).  
Prior to the advent of the CRISPR/Cas9 technology, researchers have used 
naturally occurring164 and engineered meganucleases165,166 and engineered nucleases, such 
as zinc-finger nucleases (ZFNs)167–169 and transcription-activator-like effector nucleases 
(TALENs)170–172, the latter being based on arrays of naturally occurring DNA-binding 
domains fused to a non-specific DNA-cleaving nuclease. Despite high specificity172, the 
design of engineered nucleases was complicated, with a new one being required for each 
different target locus173. Thus, CRISPR/Cas9 has come to revolutionize the field of 
genome editing with its easy programmability174,175, having made multiplexed gene 
targeting much more prompt and easy176,177.   
So far, the CRISPR genome editing system has been broadly applied in a variety of 
organisms, such as mice107,176, zebrafish178 and roundworm179, as well as in different cell 
types, such as various human cancer cell lines and human pluripotent stem cells91,180–182, 
enabling a rapid discovery of new gene functions, developing new cell and animal models 
of diseases, and making substantial biomedical progresses183.  
In the CRISPR/Cas9 system, the Cas9 endonuclease protein acts in tandem with a 
‘‘guide RNA’’ molecule, which localizes it to a specified locus in the genome, with a 
regular guide RNA: gDNA Watson-Crick base pairing following and the Cas9 promoting a 
double-strand DNA break (DSB) at the target DNA sequence162,175  
Initially two different RNA molecules, the CRISPR-RNA (crRNA) and the trans-
activating crRNA (tracrRNA), were combined to form a functional guide RNA : Cas9 
complex184. Later on it was discovered that by fusing the crRNA and the tracrRNA into a 
single-chain chimeric single-guide RNA (sgRNA), the complex was still functional and 
operated at high frequencies180. Thus, the CRISPR/Cas9 system applicability was 
simplified, requiring only one protein and one small RNA molecule to achieve RNA-
directed DNA cleavage180 . 
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In response to DSBs induced by Cas9, cellular DNA repair pathways are activated, 
which mostly lead to random insertions or deletions (indels) occurring at the site of DNA 
cleavage, repaired predominantly through the non-homologous end joining (NHEJ) 
enzymatic repair pathway185,186. However, the DNA sequences surrounding the cleavage 
site can be replaced by a homologous sequence through a less frequent homology-directed 
repair (HDR) mechanism, provided the former exists in the nucleus (G2 and S phase)185 or 
if a template donor DNA sequence is introduced. However, given that between the two 
competing processes, the NHEJ prevails upon the resolution of DSBs, indels are generally 
a more frequent outcome162,187–189 (Fig. 6b).  
Importantly, the target DNA sequence (the protospacer) must satisfy two basic 
conditions: be complementary to the guide RNA and present a ‘‘protospacer-adjacent 
motif’’ (PAM) – a short DNA sequence, usually a trinucleotide, to ensure compatibility 
with a particular Cas9 nuclease in use190.  
There are various naturally occurring CRISPR nucleases, which have been used to 
edit mammalian genomes, providing a great targeting flexibility175. Each one varies in size, 
PAM requirement, and location of the introduced DSB within the protospacer, the most 
commonly used variant being the 1,368-residue long Cas9 protein from Streptococcus 
pyogenes (SpCas9), with a “NGG” PAM (Fig 6b). This relatively simple motif of SpCas9 
occurs on average every 8–12 bp in the human genome191.  
The CRISPR/Cas9 technology application is now well established in the coding 
region, predominantly to create stable KO organisms and cell lines175,177,179,190,192–194.  
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Figure 6 – CRISPR/Cas9 mediated genome editing. a), the figure features the biogenesis and assembly of the 
CRISPR RNA (crRNA) and the trans-activating crRNA (tracrRNA), expressed from the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) type II locus of Streptococcus pyogeenes, and the 
introduction of a double strand break (DSB) in the genomic sequence, upon single guide RNA (sgRNA) 
pairing with its target, containing a protospacer adjacent motif (PAM) trinucleotide. b), there is represented a 
a) 
b) 
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resolution of a DSB by the means of a Non Homologous End Joining mechanism (left, or through Homology 
Directed Repair, with a repair template being provided (right). Figure 6a adapted from: PrecisionX™ Cas9 
SmartNuclease System Cat. # CAS8/9xxA-1, (2013)195. Figure 6b: adapted from Maclean., (2016), web 
page196 
 
 
Background and Aims 
Previous work of the lab197, has shown that the MCL1 gene harbored four canonical 
pAs in its extensive (~2,8 kb long) 3’ UTR, even though only the two most at the 3’ end 
were used in human T cells (Fig. 7). Those pAs give rise to two APA-derived mRNA 
isoforms varying only in the length of their 3’ UTRs, and whose individual functions are 
yet to be discovered. The short APA-derived isoform – pA1, has a 3’ UTR of 1418 nt long, 
while the long isoform – pA2 has a 3’UTR of 2828 nt long (Fig. 7). Whilst the pA2 mRNA 
isoform is more expressed, the pA1 isoform was the one that produced more Mcl-1 protein. 
In addition, it was shown that the pA2 isoform was down regulated by miR-17 in the 
cytoplasm197. 
 
 
Figure 7 – Scheme of the MCL1 APA-derived -mRNA isoforms. The scheme features the 5’ UTR, exons 
(boxes), and the two 3’ UTR lengths with the pA1 (top) and the pA2 (bottom) polyadenylation signals, plus 
a polyadenylate tail (An) at the end. 
 
On the background of the previous studies, the main aim of this thesis consisted in 
continuing unraveling the MCL1 regulatory landscape, by delving deeper into the 
physiological function of the two APA-derived mRNA isoforms. With that purpose, the 
first objective of this work consisted in assessing the influence of the two MCL1 APA 
isoforms on the localization of Mcl-1 protein. The second objective was to study each 
isoform separately from one another, by providing a clean, unbiased and physiological 
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approach to assess pA1 versus pA2 isoforms expression and function, by the means of 
genome engineering. Finally, it was our aim to assess whether the knock-out of two 
important genes involved in RNA processing: INTS9 and CPSF1, will impact Mcl-1 
polyadenylation process and/ or cell viability. The CPSF1 is a basic polyadenylation factor 
and the INTS9, on the other hand, is part of the Integrator complex, which was revealed to 
play a termination function at polyadenylated transcripts198. In addition, INTS9 knockdown 
may impact the expression of the MCL1 pA2 isoform, as was suggested by our group 
preliminary knockdown experiments. 
Specific aims of this thesis were to: 
a) Assess the influence of the two MCL1 APA isoforms on the localization of 
Mcl-1 protein; 
b) Optimize a method for polyadenylation signal targeting by CRISPR/Cas9 in 
difficult to transfect cells (E6.1) to generate MCL1 lacking either the proximal 
(MCL1∆pA1) or the distal (MCL1∆pA2) pA signals.  
c) Obtain CRISPR/Cas9 stable cells lines for CPSF1 and INTS9 knock-outs,  
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Materials and Methods 
 
Cell Culture 
Jurkat E6.1 suspension cell line was grown and maintained in complete RPMI 1640 
medium, supplemented with GlutaMAX and phenol red, with 10% of Fetal Bovine Serum 
(FBS) and 1% of a penicillin/ streptomycin (Pen/ Strep) antibiotic solution. Cells were 
maintained in culture at 37 ºC with 5% of CO2, in a humidified incubator, being split every 
3-4 days (cells passage). At each passage, cells were counted and re-suspended at a 1 x 106 
cells/mL concentration in fresh complete RPMI medium.   
HeLa and HEK 293T adherent cell lines were grown and maintained in complete 
DMEM medium, with 10% of FBS, and 1% of a Pen/ Strep antibiotic solution. These were 
maintained in culture at 37 ºC with 5% of CO2, in a humidified incubator. Every 3-4 days, 
cells were washed with 1x PBS, trypsinized with TRYple reagent, re-suspended in fresh 
medium and then passed into a new cell culture flask in a 1:10 dilution, in order to 
maintain subconfluency (<95%).  
All of the aforementioned reagents were provided by Gibco® (Life technologies). 
 
 
Total RNA Extraction  
Jurkat E6.1 cells were harvested [10 million (M)] by centrifuging them in a 
centrifuge tube at 300 g for 5 min. Thereafter, the supernatant was discarded, the pellet was 
washed twice with 1,5 mL of 1x PBS, centrifuging at 300 g for 5 min after each washing 
step. Then, the supernatant was removed, and 1 mL of TRIzol reagent was added to the 
pellet, homogenizing the solution completely by pipetting up-and-down with a 20 gos (G) 
needle (~15-17 times). Afterwards, chloroform was briefly added to the lysed sample in 
TRIzol reagent, in a 1:5 (v/v) ratio. The sample was shaken vigorously in order to mix the 
contents, and incubated for 3 min, at room temperature (RT). Afterwards, the sample was 
centrifuged for 15 min at 12000 g, at 4ºC, to promote the separation of the organic and 
aqueous phases. The upper aqueous phase containing total RNA was transferred into a new 
centrifuge tube on ice. Thereafter, 1 μL of glycogen (15 mg/mL, Life Technologies) and 
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one volume (v/v) of isopropanol was added to the total RNA sample to promote RNA 
precipitation. The sample was vortexed and incubated at -80ºC for at least two hours, to 
precipitate RNA. After thawing the sample at RT, it was centrifuged for 20 min at 12000 g, 
at 4ºC. The resulting RNA pellet was washed twice with 500 μL of ice cold 75% ethanol 
(EtOH) and centrifuged for 10 min at 12000 g, at 4ºC, after each washing step. The pellet 
was air dried at RT and then re-suspended in 10-30 μL of nuclease-free water (Thermo 
ScientificTM), depending on the pellet size. The sample was then stored at -80ºC, until 
being used for cDNA synthesis.  
 
 
cDNA Synthesis 
cDNA was synthesized from 1 µg of Jurkat E6.1 total RNA using the SuperScriptTM 
IV (SSIV) Reverse Transcriptase enzyme, according to the manufacturer’s protocol 
(Invitrogen, Life Technologies), subjected to minor changes. RNA samples were diluted 
into a 14 µL mix, containing nuclease-free water (HyClone™ HyPure Molecular Biology 
Grade Water, GE Healthcare), 1 μL of dNTPs (10 mM) and 1 μL of random hexamers (50 
μM). After a short spin, the mixtures were incubated at 65ºC for 5 min in order to denature 
RNA, followed by 5 min incubation on ice. Two types of a reverse transcription (RT) 
master mix were prepared: one with the SSIV enzyme (RT+) and one without the enzyme 
(RT-), a control to screen for genomic DNA contaminations. For each individual sample, 
the RT+ mixture’s contained 4 μL of a 5X SSIV cDNA synthesis buffer, 1 μL of DTT (0,1 
M), 0,5 μL of RiboLock RNase Inhibitor (40 U/μL, Thermo ScientificTM) and 0,5 μL of 
SSIV RT enzyme (200 U/μL, Invitrogen). The RT- mixture’s final composition was the 
same, except for SSIV addition, which was replaced by nuclease-free water. Samples were 
incubated for 10 min at 23ºC, then 10 min at 50ºC and finally 10 min at 80ºC to heat-
inactivate the enzyme, using a personal thermocycler (Biometra).  
 
 
Polymerase Chain Reaction (PCR)  
Primers with overhangs – 5’ CACAGATCTATGTTTGGCCTCAA 3’ Forward (F) 
and 5’ CACGAGCTCCTATCTTATTAGAT 3’ Reverse (R), were used to amplify MCL1 
coding sequence (CDS) (1050 bp) containing restriction digestion sites for BglII at the 5’ 
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end and for SacI at the 3’ end (bold sequences), for cloning into a pEGFP-C1 expression 
vector (Clontech). The reaction mix for each individual sample contained; nuclease-free 
water, 2 µL of a cDNA sample (previously synthesized from 1 µg of RNA from Jurkat 
E6.1), 0,2 µL of GoTaq Flexi® DNA Polymerase (#M829A, Promega – 100 U/mL), 4 µL 
of 5x GoTaq Flexi® Green buffer, 1,5 µL of MgCl2 (25 mM), 1 µL of dNTP mix (10 mM) 
and 1 µL of each F and R primer (10 µM), in a total volume of 20 µL. Samples were 
amplified for 37 cycles at 95ºC for 30 s, 58ºC for 30 s, and 72ºC for 60 s, after an initial 
denaturation step at 95ºC for 3 min, and followed by a final extension step of 5 min at 72ºC 
in a personal thermocycler (Biometra). 
 
 
Agarose Gel Electrophoresis  
Three µL of SYBR® safe fluorescent nucleic acid dye were used per each 100 mL 
of 1x TAE (Tris Acetate-EDTA) running buffer. A GeneRulerTM Ladder Mix (Invitrogen 
Corporation) was used as a molecular weight marker. After completion of PCR reaction, 
total volumes of the mixes were loaded on a 1% agarose gel and, after 1 h electrophoresis 
at 120 V, the bands corresponding to the MCL1 CDS PCR product were excised and then 
subjected to the Sephadex DNA extraction protocol (see protocol below). 
 
 
DNA Extraction from Agarose Bands  
DNA agarose bands were cut from the agarose gel and placed at -80ºC for at least 
20 min. To favor the DNA detachment from the agarose, the 1,5 mL centrifuge tubes 
containing the bands were incubated for 10 min at 42ºC. Sephadex G-50 (GE Healthcare) 
fine resine-coated columns were prepared in advance, with 850 µL of Sephadex slurry 
being pipetted into Zymo-Spin columns (with their silica part being previously removed), 
centrifuging for 4 min at 2200 g. The columns were then transferred to 1,5 mL centrifuge 
tubes. After incubation, the partially liquefied agarose bands were vortexed and transferred 
to their respective Sephadex-coated columns, which were then centrifuged for 10 min at 
4400 g. The Sephadex-coated columns filtered out small DNA fragments and agarose, with 
the DNA sample being eluted into the flow-through. In order to perform DNA ethanol 
precipitation, 1 µL of glycogen – 20 mg/mL (Roche Diagnostics), 10/3 of absolute ethanol 
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and 1/3 of ammonium acetate (NH4CH3CO2) – 10 M, were added to the samples’ volumes, 
in centrifuge tubes. Samples were then vortexed and centrifuged for 5 min at 14000 g. The 
resulting pellets were washed with 1 mL of 70% EtOH and centrifuged for 5 min at 14000 
g. The DNA pellets were air dried, re-suspended in 10 µL of nuclease-free water and 
quantified with Nanodrop. 
 
 
Plasmid Cloning 
Firstly, to generate the pEGFP (Enhanced Green Fluorescent Protein) MCL1 CDS 
plasmid, the MCL1 CDS PCR product amplified from E6.1 cDNA was cloned into the 
pEGFP-C1 expression vector (Clontech), by performing a sequential digestion using two 
restriction enzymes on both the insert and vector DNAs. BglII (NEBTM – 10,000 U/mL) 
was used to cut at the 5’ end and SacI (NEBTM – 20,000 U/mL) was used to cut at the 3’ 
end. The 100 µL restriction mixes for BglII contained: sterile water, 10 µL of 10x NEBTM 
3.1 buffer, 3 µg of DNA sample and 1 µL of restriction enzyme. Also, a non-cut control 
without restriction enzyme was made for the vector. After 2 h digestion at 37ºC, 100 µL of 
sterile water was added to the samples, followed by the addition of one volume of Phenol/ 
Chloroform/ Isoamyl Alcohol solution (25:24:1; Sigma). The samples were vortexed and 
centrifuged for 5 min at 14000 g, and the aqueous phases were recovered and subjected to 
EtOH precipitation, as described above. DNA pellets were re-suspended in 44 µL of sterile 
water, with 5 µL of 10x NEBTM 1.1 buffer and 1 µL of SacI enzyme being added. SacI 
digestion was performed for 2 h, at 37ºC. Then, 1 µL of FastAP thermosensitive alkaline 
phosphatase (Thermo Scientific™ – 1 U/µL) was added to the vector and incubated for 30 
min at 37ºC. Thereafter, the enzymes were heat-inactivated, by incubation at 65ºC for 20 
min. Samples were loaded into a 0,8% agarose gel, and the bands corresponding to the 
inserts and vector were excised to purify DNA through the Sephadex protocol (see section 
above). Then, a subcloning step was performed, consisting in the addition of MCL1 3’ 
UTR sequences downstream of CDS, namely: a short pA1 isoform 3’ UTR, a long pA2 
isoform 3’ UTR or a pA2 isoform 3’ UTR with a mutated miR-17 binding site. The two 
pA2 isoform 3’ UTR sequences had the upstream pA1 signal mutated. Thus, to generate 
the following plasmids: pEGFP MCL1 CDS pA1, pEGFP MCL1 CDS pA2 and pEGFP 
MCL1 CDS pA2∆mir17, SacI – at the 5’ end, and SalI (NEBTM – 100,000 U/mL, 
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10xNEBTM 3.1 buffer) – at the 3’ end, restriction enzymes were used as described above to 
cut the pEGFP MCL1 CDS vector and the inserts from already available pEGFP-pA1/ 
pA2/ Luc-pA2∆mir17 plasmids.   
 
 
DNA Insert Sticky-End Ligation Into Vector DNA  
Firstly, the NEB Biocalculator online software was used to determine the mass (ng) 
of insert that should be used in a ligation reaction at a given insert to vector DNA molar 
ratio (3:1 ; 5:1). The lengths of insert (MCL1 CDS PCR product –1050 bp; pA1 isoform 3’ 
UTR –  1418 bp; pA2 isoform 3’ UTR –  2828 bp, and pA2∆mir17 isoform 3’UTR – 2828 
bp) and vector DNA (pEGFP-C1 – ~4,7 kb , pEGFP MCL1 CDS – ~5,8 kb ), as well as the 
set mass of linear vector DNA (100-150 ng) were taken into account. Each ligation mix, 
besides vector and insert DNA samples, contained sterile water, 1 µL of T4 DNA Ligase 
(#EL0011, Thermo Scientific™ – 5 U/µL) and 2 µL of 10x T4 DNA Ligase Buffer, in a 
total reaction volume of 20 µL. Also, two controls were made for each vector-insert 
combination: Vector + Ligase and Vector – Ligase, in order to provide a background 
reference at the transformation step, in terms of the number of colonies. After 2 h 
incubation at 22ºC, the T4 DNA Ligase enzyme was heat inactivated, by incubating at 
65ºC for 10 min. All reagents were provided by Thermo Scientific™. 
 
 
Transformation Of Chemically Competent Bacteria 
The ligation solution containing plasmid DNA was added in a 1:10 (v/v) ratio to the 
100 µL of Top10 E.coli strain chemically competent bacteria, incubating on ice for 15 min. 
Then, a heat-shock was performed by incubation for exactly 1 min at 42ºC, in a thermostat 
(Eppendorf). Thereafter, the transformation mixes were once again incubated on ice for 5 
min, followed by an addition of 4 volumes of a Luria-Bertani (LB) broth medium. The 
transformants were incubated in an orbital shaker for 1 h at 37ºC. The transformation 
mixes were plated out on petri dishes containing LB agar selection medium supplemented 
with 50 µg/mL Kanamycin or 100 µg/mL Ampicillin, depending on the selection marker 
encoded in the vector. The volume and concentration of transformed E. coli varied with the 
type of vector being used. For plasmid transformation, 10 µL of bacterial suspension was 
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plated out directly, whereas for ligation mixes, cells were centrifuged at 400 g for 2 min, 
with most of the supernatant being discarded and the whole pellet re-suspended in the 
remaining supernatant being plated out. Petri plates were incubated overnight (O/N) at 
37ºC and cell growth was assessed on the following day, with round isolated colonies 
being selected for colony PCR or inoculation. 
 
 
Colony PCR 
For one sample, the colony PCR reaction mix had a total volume of 10 µL, 
containing; 5,6 µL of sterile water, 2 µL of 5x GoTaq® Flexi polymerase Green buffer 
(Promega Corporation), 0,75 µL of MgCl2 solution (25 mM), 0,5 µL of dNTPs mix (10 
mM), 0,5 µL of each – forward and reverse, primer (10 µM) and 0,15 µL of GoTaq® Flexi 
polymerase enzyme (Promega Corporation). Only isolated colonies were picked for the 
colony PCR reaction. In parallel, same colonies were inoculated into their corresponding 
wells on a 96-well cell culture plate.  To this end, 100 µL of LB broth medium 
supplemented with antibiotic was pipetted per well in advance, accounting for samples and 
one negative control. Thus, colonies were sequentially dipped into their respective PCR 
mixes, using pipette tips, and then into the cell culture plate wells. A clean pipette tip was 
placed into the negative control PCR tube and well. . Samples were amplified for 35 cycles 
at 95ºC for 45 s, at Ta (temperature of primers annealing –adjusted) for 45 s, and at 72ºC 
for a time depending on the amplicon size (~1 min/ 1kb), after an initial cell lysis/ 
denaturation step at 95ºC for 5 min, and followed by a final extension step of 5 min at 72ºC 
in a personal thermocycler (Biometra). 
Throughout the PCR reaction, the inoculated clones were incubated at 37ºC. After 
completion, whole PCR reaction volumes were loaded into a 1% agarose gel and run for 
~30 min at 120 V. After electrophoretic profile analysis, the alleged positive clones were 
inoculated in 5 mL of LB broth supplemented with antibiotic.  
 
 
Plasmid DNA Extraction  
The ZR Plasmid MiniprepTM kit (ZYMO Research) protocol subjected to minor 
changes was applied to extract the plasmid DNA from the transformed competent bacteria. 
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Firstly, to obtain a 4,5 mL-E. coli suspension pellet, the same centrifuge tube was filled 
thrice at maximum capacity, centrifuging at 16000 g for 30 sec, and discarding the 
supernatant. Thereafter, 200 µL of P1 Buffer was added to the tube, and the pellet was re-
suspended completely by vortexing. Afterwards, 200 µL of P2 Buffer was added to the cell 
suspension, mixing contents by inverting 4 times and letting the solution incubate for 2 
min at RT, to promote cell lysis. P3 buffer (400 µL) was added to the tube, mixing 
contents by inverting 4-5 times and incubating the lysate for 2 min at RT, to promote 
neutralization. Thereafter, the sample was centrifuged at 16000 g for 4 min, and the 
supernatant containing plasmid DNA was carefully transferred to a Zymo-Spin IIN column 
placed into a collection tube. This Zymo-Spin IIN assembly was centrifuged for 30 sec at 
16000 g, the flow-through was discarded, and 200 µL of Endo-Wash Buffer were added to 
the column. The assembly was centrifuged for 30 sec at 16000 g, and 400 µL of Plasmid 
Wash Buffer was added, centrifuging the assembly for 1 min at 16000 g. Lastly, the 
plasmid DNA was eluted in 30 µL of nuclease-free water into a clean centrifuge tube, by 
adding water directly to the column matrix, incubating for 1 min at RT, and then 
centrifuging for 1 min at 16000 g. The eluted plasmid solution was stored at -20ºC. All 
plasmids were sequenced on an ABI 3130XL Automated Sequencer (Applied Biosystems) 
to confirm that they had been accurately constructed.  
 
 
HeLa Cells Transfection  
For each experiment condition, 120 000 HeLa cells were seeded the day before 
transfection on a µ-Slide 4 Well Glass Bottom (Ibidi®), in 750 µL of complete DMEM 
medium and at standard culture conditions, to reach a 60–80% confluency. HeLa cells 
transfection with EGFP-containing constructs, namely: pEGFP MCL1 CDS pA1, pEGFP 
MCL1 CDS pA2 and pEGFP MCL1 CDS pA2∆mir17, was carried out the day after 
seeding using the jetPRIME transfection reagent (Polyplus-transfection®), according to the 
manufacturer’s standard protocol. Briefly, media were removed from the cells, and 500 µL 
of fresh media without Pen/ Strep was added per well. Afterwards, 0,5 g of each EGFP-
containing construct was diluted in 50 µL of jetPRIME buffer, with the solutions being 
vortexed for 10 sec and then short-spinned. One µL of jetPRIME reagent was added to the 
previous solutions in a 1:2 plasmid weight per volume of jetPRIME reagent proportion 
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(w/v). The solutions were vortexed for 10 sec, short-spinned and incubated for 10 min at 
RT, to form micelles. After that, the transfection mixtures were added dropwise to the 
cells, being homogenized by rocking the cell culture vessel. Media were replaced by 750 
µL of complete DMEM media 4-24 hrs after transfection. HeLa transfection efficiency was 
assessed 48 h post transfection, through observation of the EGFP fluorescence in a ZOE 
inverted fluorescence microscope (Bio-Rad).  
 
 
MitoTracker Red and Hoechst Live Cell Staining 
Firstly, the media were removed from the µ-Slide 4 Well Glass Bottom (Ibidi®) 
wells. Then, for mitochondria staining, cells were incubated in 500 µL of complete DMEM 
medium supplemented with 50 nM of MitoTracker Red solution (Thermo ScientificTM), for 
1 h, at 37ºC, in a 5% CO2 humidified incubator. Thereafter, for nuclei staining, cells were 
washed twice with 1x PBS and then incubated in 500 µL of complete DMEM medium 
supplemented with 0,5 µg/mL of Hoechst 33342 (Thermo ScientificTM), for 30 min at 37ºC 
in a 5% CO2 humidified incubator. Cells were washed twice with 1x PBS and then, 500 µL 
of a 1% FBS/ HBSS solution was added to the samples.  
 
 
Confocal Microscopy Live Cell Imaging 
Images were acquired in a Sp5 inverted confocal microscope (Leica), using the 
63X oil objective with a 1024x1024 pixel resolution. The settings were maintained the 
same for all of the three constructs (pEGFP MCL1 CDS pA1, pEGFP MCL1 CDS pA2 
and pEGFP MCL1 CDS pA2∆mir17), with the following lasers set being used: 405 nm for 
Hoechst, 488 nm for EGFP and 561 nm for MitoTracker Red. Images were processed and 
analyzed using the FIJI package for Image J software. To quantify EGFP fluorescence 
intensity, firstly, the areas and the mean fluorescence intensity values (in arbitrary units – 
a.u.) for each transfected cell were measured using the ROI (Regions Of Interest) manager 
tool available in the ImageJ software. Thereafter, those mean fluorescence intensity values 
were corrected by subtracting the mean value of background fluorescence intensity and the 
obtained values were then multiplied by the area of each cell, with total fluorescence 
intensity levels being thus quantified for ~50 cells per each transfection condition (pEGFP 
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MCL1 CDS pA1/ -pA2 and -pA2∆miR17). In order to quantify statistical differences, the 
total fluorescence intensity values for cells in each of these three conditions were uploaded 
into the GraphPad Prism 7.04 software. Then, an unpaired t test with Welch's correction 
was applied to the pEGFP MCL1 CDS pA1 vs -pA2 and -pA2 vs -pA2∆miR17 datasets.  
 
 
Guide RNAs Design Strategy 
In order to obtain CPSF1 and INTS9 gene knock-outs (KO) as well as MCL1∆pA1 
and MCL1∆pA2 Jurkat E6.1 stable cell lines, a CRISPR/Cas9 approach was chosen and 
guide RNAs (gRNAs) were designed using the “CRISPR Design” online software 
(available on http://crispr.mit.edu/). The gRNA selection was based on score and on the 
number of off-targets. Guide RNA oligo sequences, scores and the number of off-targets 
are listed in table 1. For CPSF1 and INTS9 gene knock-outs, one pair of guides (one 
upstream and one downstream) was designed, matching the coding sequence. For 
MCL1∆pA1, a single-guide (MCL1∆pA1s) as well as a double-guide (MCL1∆pA1d) 
strategy was developed. The former consisted in the double gRNA targeting of the pA1 
signal neighboring region (with a predicted cleavage site being only 5 nt apart from the 
hexamer), while the latter consisted in the targeting of genome sequences upstream and 
downstream of the pA1 signal, to delete a ~70 nt region including the pA1 signal. For 
MCL1∆pA2, two different pairs of gRNAs were designed: upstream and downstream of 
the pA2 signal. These guides created a deletion (1st guide pairs around 200 nt and 2nd guide 
pairs around 300 nt) including the pA2 signal and its respective neighboring region.  
For each gRNA, a forward (F) and a reverse (R) oligonucleotide (oligo) was 
ordered (table 1). The F oligo contained a 5’ end – “CACCG” overhang, whereas the R 
oligo contained a 5’ – “AAAC”, together with a 3’ end – “C”, overhangs. These overhangs 
were designed with a purpose to provide BsmBI restriction enzyme sites, for cloning into 
the all-in-one lentiCRISPR v2 (#52961, Addgene) lentiviral vector (see section bellow: 
gRNAs Cloning Into The All-in-One Vector). 
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Table 1 – Guide RNAs oligonucleotides list and guides features. 
 
Guide RNA oligo name Target region Sequence (5'-3') with overhangs Score http://crispr.mit.edu/ Strand Sequence lenght
CPSF1_gRNA1-F caccgATGTACACACGCCGCGAGTG
CPSF1_gRNA1-R aaacCACTCGCGGCGTGTGTACATc
CPSF1_gRNA2-F caccgCCATGCTTGTCTACGGCACG
CPSF1_gRNA2-R aaacCGTGCCGTAGACAAGCATGGc
INTS9_gRNA1-F caccgACGGAACCCACCGTCCAGAT
INTS9_gRNA1-R aaacATCTGGACGGTGGGTTCCGTc
INTS9_gRNA2-F caccgACCGAGCACACCGGCTTCAC
INTS9_gRNA2-R aaacGTGAAGCCGGTGTGCTCGGTc
pA1single_gRNA-F caccgATTTGCTTTATTGACATACT 
pA1single_gRNA-R aaacAGTATGTCAATAAAGCAAATc
pA1up_gRNA-F caccgGGCTTGCTTGTTACACACAC
pA1up_gRNA-R aaacGTGTGTGTAACAAGCAAGCCc
pA1down_gRNA-F caccgCAATGCAAAAACTTGCAACA
pA1down_gRNA-R aaacTGTTGCAAGTTTTTGCATTGc
pA2up1_gRNA-F caccgGTTCGGGCAAATCCTCCAAA
pA2up1_gRNA-R aaacTTTGGAGGATTTGCCCGAACc
pA2up2_gRNA-F caccgGCTGACTGGCTACGTAGTTC
pA2up2_gRNA-R aaacGAACTACGTAGCCAGTCAGCc
pA2down1_gRNA-F caccgTCAAATACAGGGTGTGATAT
pA2down1_gRNA-R aaacATATCACACCCTGTATTTGAc
pA2down2_gRNA-F caccgTCAGCTGAGCAAATATGTAC
pA2down2_gRNA-R aaacGTACATATTTGCTCAGCTGAc
CPSF1
INTS9
MCL1 pA1
MCL1 pA2
96
95
93
88
42
79
60
79
92
74
70
(+)
25(+)
(-)
(+)
(+)
(+)
(+)
(+)
(+)
(+)
(-)
 
 
 
LentiCRISPR v2 Plasmid Purification 
The all-in-one lentiCRISPR v2 (Addgene #52961) lentiviral vector, encoding a 
humanized Streptococcus pyogenes Cas9 (hSpCas9) and the BsmBI restriction site for 
insertion of a guide RNA sequence, was purified using the HiSpeed® Plasmid Purification 
Maxi Kit (Qiagen) using the manufacturer’s protocol instructions being eluted in 500 µL of 
nuclease-free water. This plasmid was digested with a BsmBI (NEBTM – 10,000 U/mL), 
being thereafter purified from the agarose gel using the Sephadex protocol (see section 
above). 
 
 
gRNAs Cloning Into The lentiCRISPR v2 All-in-One Vector  
The gRNAs’ F and R oligos were annealed and then cloned individually into the 
all-in-one lentiCRISPR v2 lentiviral vector previously digested with BsmBI. Firstly, 1 µL 
of forward and 1 µL of reverse oligo (100 µM) for each of the 11 gRNAs pairs (table 1), 
were combined in a 50 µL mix, also containing 5 µL of a T4 DNA Ligase 10x buffer and 
sterile water. The annealing reactions were put in a thermocycler at 95ºC for 5 min, being 
finally cooled down to 25ºC, at a 5ºC/min rate. Thereafter, the annealed oligos mixes were 
diluted at a 1:10 dilution into sterile water. Afterwards, 2 µL of T4 DNA Ligase 10x 
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buffer, 1 µL of T4 DNA Ligase enzyme, 1 µL of a diluted annealed oligos solution (insert) 
and 1 µL of the lentiCRISPR v2 vector were combined in a ligation mix, brought up to 20 
µL with nuclease-free water, for each of the 11 constructs. The inserts’ and the vector’s 
DNAs sticky ends were ligated as described in the above section “DNA Insert Sticky-End 
Ligation Into Vector DNA”. The obtained constructs thus contained the chimeric single 
guide RNA (tracrRNA fused with gRNA: sgRNA) and the hSpCas9 expression cassettes – 
pLenti –sgRNA constructs. Thereafter, those were transformed in chemically competent 
bacteria (see section above), with the trasnformants being plated ot on LB agar plates 
supplemented with 100 µg/mL ampicillin. A colony PCR was performed using the primers 
listed below (table 2). Guide RNA sequences with a 5’ overhang were used as the forward 
primers, and a sequence matching the lentiCRISPR v2 backbone was used as a common 
reverse primer. Thereafter, positive clones were inoculated and the plasmids extracted 
using the ZR Plasmid MiniprepTM kit (see the “Plasmid Extraction” section above). All 
obtained plasmids were sequenced as referred in the “Plasmid Extraction” above. 
 
Table 2 – Colony PCR primer list for the pLenti – sgRNA constructs. 
 
 
Primer Forward (F) 
 
Primer F sequence 
Primer 
Reverse (R) 
 
Primer R sequence 
CPSF1_gRNA1-F caccgATGTACACACGCCGCGAGTG  
 
 
 
 
 
 
Lenticrispr-R 
 
 
 
 
 
 
 
TGGCACCGAGTCGGTGCTT 
CPSF1_gRNA2-F caccgCCATGCTTGTCTACGGCACG 
INTS9_gRNA1-F caccgACGGAACCCACCGTCCAGAT 
INTS9_gRNA2-F caccgACCGAGCACACCGGCTTCAC 
pA1single_gRNA-F caccgATTTGCTTTATTGACATACT  
pA1up_gRNA-F caccgGGCTTGCTTGTTACACACAC 
pA1down_gRNA-F caccgCAATGCAAAAACTTGCAACA 
pA2up1_gRNA-F caccgGTTCGGGCAAATCCTCCAAA 
pA2up2_gRNA-F caccgGCTGACTGGCTACGTAGTTC 
pA2down1_gRNA-F caccgTCAAATACAGGGTGTGATAT 
pA2down2_gRNA-F caccgTCAGCTGAGCAAATATGTAC 
 
 
Packing 293T Cell Line Transfection  
Three hundred thousand HEK 293T cells were seeded in a 6-well cell culture plate 
for each of the eleven pLenti – sgRNA constructs (see sections above) to be transfected, 
plus one non-transfected control. Twenty-four hours after cell seeding, cells were 
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transfected using a standard manufacturer’s “jetPRIME® in vitro DNA & siRNA 
transfection reagent” protocol (Polyplus®). Three vectors were co-transfected: a packaging 
plasmid – pCMV-dR8.91 (Addgene), an envelope plasmid (pMD4) and a transfer vector: 
lentiCRISPR v2 constructs with guide RNAs and Cas9. For a total plasmid mass of 2 µg, 
different mass ratios of the three types of plasmids were used:  850 ng for the lentiCRISPR 
v2 construct, 750 ng for pCMV-dR8.91 and 400 ng for pMD4. The masses of the plasmids 
used were based on their size – the bigger ones were transfected in higher proportion.  
 
 
Lentiviral Transduction 
Eight pLenti – sgRNA constructs conditions were planned out, by using eleven 
sgRNAs (table 1) lentiviral constructs: CPSF1 KO – upstream (up) and downstream 
(down) guide; INTS9 KO – up + down guide;  MCL1∆pA1s – single guide;  MCL1∆pA1d 
(double guide) – up + down guides; MCL1∆pA2d – up1 + down1,  up2 + down2, up1 + 
down2 and up2 + down1 guides. As lentiviral transduction was to be carried out in Jurkat 
E6.1 cells, DMEM media were replaced by complete RPMI media 4 h after packing 293T 
cell line transfection. Forty eight hours post-transfection, the lentiviral particles-containing 
293T media were collected into 15 mL falcons. Those were centrifuged at 3000 rpm for 5 
min at RT, to get rid of any 293T cells and debris, thereafter transferring the virus-
containing supernatants into new falcon tubes. For each experiment condition, 1 x 106 
Jurkat E6.1 cells were re-suspended in 2 mL of virus supernatant and transferred to T25 
flasks. When combining lentiviruses, 1 mL of each virus supernatant was used (storing the 
remainder at -80ºC). Three mL of fresh RPMI complete media was added to each T25, 
with the media final volume being then supplemented with 8 µg/mL of Polybrene (polyB). 
Seventy-two hours past, the media were changed, with the cells being re-suspended in 
fresh RPMI complete media supplemented with 5 µg/mL of puromycin (antibiotic 
resistance encoded in the lentiCRISPR v2 vector backbone).  
 
 
Genomic DNA Extraction From Cell Lines 
One mL of E6.1 cell suspension from each pLenti – sgRNA constructs  (see in the 
section above) was collected in an eppendorf tube and centrifuged for 5 min at 300 g. 
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Pellets were washed with 1 mL of 1x PBS, centrifuged, and then re-suspended in 500 µL 
of 1x STE buffer (100 mM NaCl, 10 mM Tris-Cl, pH 8.0 and 1 mM EDTA). Twenty-five 
microliters of SDS 20% and 10 µL of proteinase K (20 mg/mL) was added to the samples. 
Samples were incubated O/N at 56C, in an orbital shaker. On the next day, 20 µL of 5M 
NaCl solution was added to the samples. Then, in a fume hood, 550 µL of a Phenol: 
Chloroform: Isoamyl Alcohol (25:24:1) solution was added. Samples were vortexed and 
then centrifuged for 5 min at 14000 g at RT. Five hundred and fifty microliters of 
chloroform was added to the recovered aqueous phases and samples were vortexed and 
centrifuged for 5 min at 14000 g, at RT. Aqueous phases were recovered once again (~500 
µL), and 1 mL of absolute ethanol (~2 volumes), 50 µL of Sodium Acetate 3M pH 5.2 
(~1/10 volume) and 1 µL of glycogen (20 mg/mL) was added. Thereafter, samples were 
incubated for at least 2 h at -80C, to precipitate DNA. Then, those were centrifuged for 20 
min at 4C at top speed, and the supernatants were discarded. DNA pellets were washed 
with 1 mL of 70% EtOH, being centrifuged for 10 min at 4C at top speed. Finally, pellets 
were air dried and re-suspended in 50 µL of nuclease-free water. 
 
 
Genomic DNA Extraction From E6.1 Growing in a 96-well Plate 
The 96-well plates containing Jurkat E6.1 were centrifuged at 500 g for 5 min to 
pellet the cells and media were removed. Thereafter, cells were washed once with 150 µL 
of 1x PBS and 50 µL of Bradley Lysis Buffer (10 mM Tris‐ HCl (pH 7.5), 10 mM EDTA, 
0.5 % SDS and 10 mM NaCl) supplemented with 1 mg/mL of proteinase K was added to 
the samples’ wells. After that, the lid was replaced and the plate was sealed with parafilm, 
being incubated O/N at 60ºC, in a humidified chamber. After being cooled down to RT, 
100 µL of an ice‐ cold EtOH/NaCl solution (75 mM NaCl in 100% EtOH) was added to 
the samples to precipitate DNA, mixing well the contents. After incubation at RT for 30 
min, the plate was centrifuged for 20 min at 3000 rpm, the supernatant was removed and 
the pellets were rinsed twice with 150 µL of ice-cold 70% EtOH, centrifuging the plate for 
10 min, at 3000 rpm. Afterwards, the supernatants were discarded and the DNA pellets 
were allowed to air‐ dry and ressuspended in 30 µL of warm nuclease-free water. The 96-
well plate was incubated at 56 ºC for 10 min to promote DNA pellets resuspension. 
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Samples were quantified using a Nanodrop™ 1000 Spectrophotometer (Thermo 
ScientificTM). 
 
CRISPR/Cas9-subjected Cells Genotyping 
Genotyping was performed on each of the 8 pLenti – sgRNA constructs conditions 
on bulk E6.1 cell populations with 10 days of puromycin selection, and on clonal 
populations derived from single-cell sorting into 96-well cell culture plates (see section 
below). A PCR reaction mix for an individual sample contained: 4 µL of 5x GoTaq Flexi® 
Green buffer, 1,5 µL of MgCl2 (25 mM), 1 µL of a dNTPs mix (10 mM), 1 µL of each 
primer (10 µM) – forward and reverse (table 3), 0,2 µL of GoTaq Flexi® polymerase 
(#M829A, Promega – 100 U/mL) and 1 µL of gDNA sample (~50 ng/µL). The mix’s 
volume was completed to 20 µL by adding nuclease-free water. 
Table 3 – Primers used for genotyping. 
 
Target 
gene 
Primer Sequence Amplicon size 
w/o deletion (bp) 
CPSF1 PCR1_2-F TTCTGTGGCCCCAAGTGTTT 250 
PCR1_2-R CACCACAGCCTGCCTCAG 
INTS9 PCR3_4-F ATTCCCTCCCTTTCTTTTCAGACG 267 
PCR3_4-R TCAGAAGGAACTAACCACCAGC 
MCL1 pA1 MCL1_pA1.2-F GATGGCTTGGAAAAGCAGGC 254 
MCL1pA1-R-XL ATC TGT AGA GGG AGC AGA AC 
MCL1 pA2 MCL1_pA2-F2 GGAGGAGGAGGCAGGTGGT 671 
PCR_891011-R GAGGTTTTTGATTTTACTTGGAGGT 
 
Jurkat E6.1 Single-Cell Sorting  
Jurkat E6.1 bulk cell populations were subjected to single-cell sorting into 96-well 
cell culture plates – 2 plates per condition. In advance, 150 µL of complete RPMI medium 
were added to each well of 96-well cell culture plates. Two millions of cells from each 
condition were centrifuged at 300 g for 5 min, the supernatants were discarded and cells re-
suspended in 500 µL of a Fluorescence Activated Cell Sorting (FACS) buffer (2% FBS, 5 
mM EDTA and 0,1% sodium azide in 1x PBS; stored at 4ºC) and then filtered through 0,2 
mm cell strainers into FACS tubes. Single-cell sorting was performed using the FACS Aria 
II Cell Sorter (BD Biosciences). After the single-cell sorting procedure, cells were put at 
standard culture conditions, with clonal populations being split between two 96-well 
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plates: one for being used for genotyping (see section above), and one for maintaining in 
culture in the event of the clone being deletion positive. 
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Results 
Intracellular Distribution of Mcl-1 Varies According to Its Transcript’s 3’ UTR Length   
The discovery made by Mayr and Berkovits52 showing that the 3’ UTR can 
modulate differential protein localization, prompted us to investigate whether the cellular 
distribution of the Mcl-1 protein varied when translated from the mRNA containing the 
short (1418 nt- pA1) or the long (2828 nt - pA2) 3’UTR. Previously, our group has mapped 
the two MCL1 APA-derived mRNA isoforms in HeLa cells by 3’ RACE (Rapid 
amplification of cDNA ends). Given that the HeLa cell line is very amenable to work with, 
such as carrying on overexpression studies through transient transfection, and that E6.1 
cells are, in contrast, very difficult to transfect, we decided to perform subcellular 
localization studies in the HeLa cell line. In order to do so, the following expression 
constructs featuring a MCL1 coding sequence (CDS) followed by either the short or the 
long 3’ UTR sequences were made and transfected into HeLa cells: pEGFP MCL1 CDS 
pA1 (thereafter referred to as –pA1) and pEGFP MCL1 CDS pA2 (thereafter referred to as 
–pA2), with the upstream pA1 mutated. Subcellular localization was analysed by 
microscopy and the settings of image acquisition in the Sp5 confocal microscope were 
maintained the same for the two constructs. After being acquired in a 1024x1024 pixel 
format, the images from the three fluorescence channels (EGFP – EGFP-fused Mcl-1; 
Mitotracker Red (Mito. Red) – mitochondria and Hoechst –nuclei) were merged using the 
ImageJ software (Fig. 8, 9). 
The Mcl-1 protein expressed from the pEGFP MCL1 CDS pA1 construct showed a well-
defined mitochondrial enrichment, with relatively little cytoplasmic and nuclear 
localization (Fig. 8a). On the other hand, Mcl-1 expressed from the pEGFP MCL1 CDS 
pA2 construct, presented a markedly different localization profile in comparison to the 
previous construct. Expression of Mcl-1 from this construct is ubiquitous and disperse, 
showing cytoplasmic and nuclear labelling, and also presenting cytoplasmic speckles (Fig. 
9). 
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Figure 8 – Mcl-1 cellular localization in HeLa cells, when expressed from the pEGFP MCL1 CDS pA1 
construct. On   the left column, there are split channels (EGFP: EGFP-fused Mcl-1; Mito. Red: mitochondria; 
Hoechst: nuclei). 
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Figure 9 – Mcl-1 cellular localization in HeLa cells, when expressed from the pEGFP MCL1 CDS pA2 
construct. On the left column, there are split channels (EGFP: EGFP-fused Mcl-1; Mito. Red: mitochondria; 
Hoechst: nuclei.) On the right, there is a merged image of the three channels. In a) the GFP channel 
fluorescence intensity was maintained according to the parameters set when acquiring images in the Sp5 
confocal microscope. The fluorescence intensity in on this image was enhanced using ImageJ to facilitate the 
visualization of the EGFP-Mcl-1 protein. 
 
 
Mitochondria Morphology Is Altered Upon Overexpression Of Mcl-1 From The pEGFP 
MCL1 CDS pA1 Construct 
In comparison to the non-transfected cells, cells transfected with the pEGFP MCL1 
CDS pA1 construct presented an altered mitochondrial structure, consisting in its shifting 
from a ring appearance to a more agglomerated phenotype (Fig. 10b). This altered 
morphology was not observed in cells transfected with the pA2 construct (Fig 9). 
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Figure 10 –Mitochondria morphology in HeLa cells changes upon overexpression of Mcl-1 from the pEGFP 
MCL1 CDS pA1 expression construct. a) merged image (EGFP: EGFP-fused Mcl-1; Mito.Red: 
mitochondria; Hoechst: nuclei). b) image depicting mitochondria, using a Mito.Red channel. The transfected 
cells [white arrows in b)], present a more agglomerated phenotype in comparison to the non-transfected cells, 
which feature a ring morphology. 
 
The Short pA1 mRNA Isoform Produces More Protein Than pA2 
Given that we observed clear differences in EGFP fluorescence intensity between -
pA1 and -pA2 EGFP-constructs in the confocal microscope (Fig. 8, 9), we proceeded to 
EGFP fluorescence quantification (Fig. 11). Firstly, the areas and the mean fluorescence 
intensity values for each transfected cell were measured using the ROI (Regions Of 
Interest) manager tool available in the ImageJ software. Thereafter, those mean 
fluorescence intensity values were corrected by subtracting the mean value of background 
fluorescence intensity and the obtained values were then multiplied by the area of each 
cell, with total fluorescence intensity levels being thus quantified for ~50 cells per each 
condition (-pA1 and -pA2). Afterwards, some outliers were eliminated from each group, 
with data from a total of 45 cells for each condition being thus used downstream. 
In order to quantify the differences in EGFP intensity, the total fluorescence 
intensity values for 45 cells in the two transfection conditions were uploaded into the 
GraphPad Prism 7.04 software. Then, an unpaired t test with Welch's correction was 
applied to the datasets, which showed a highly significant difference (p < 0,0001) between 
the means of -pA1 (3682572 arbitrary units – a.u.) and -pA2 (1138887 a.u.), Thus, the 
a) b) b) 
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mean value of -pA1 total fluorescence intensity is approximately three times higher than 
the one of -pA2 (Fig. 11).  
 
 
 
Figure 11 – Fluorescence intensity quantification for the pEGFP MCL1 CDS pA1 and -pA2 constructs. A 
total of 45 cells in both depicted transfection conditions were quantified, with the fluorescence intensity 
being measured in arbitrary units (a.u). The difference between the two datasets means was highly 
significant, being thus depicted by four asterisks (**** p< 0.001).  For statistical analysis, an unpaired t test 
with Welch's correction was performed. This result is representative of three experiments (n=3). 
 
 
miR-17 Is Not Responsible for pA2-derived Mcl-1 Expression and Subcellular Localization 
Given that we detected a ~3 fold higher fluorescence intensity in the -pA1 
construct, we decided to transfect the pEGFP MCL1 CDS pA2∆miR17 expression 
construct, with a mutated miR-17 binding site, alongside the pA1 mutation. As the miR-17 
was previously shown by our group to bind only the long pA2 MCL1 APA-derived mRNA 
isoform, we sought to discover whether the fluorescence intensity, which positively 
correlates with protein levels, would be enhanced upon inhibiting miR-17-mediated 
regulation of the –pA2 isoform.  
However, the difference between the EGFP fluorescence intensity means of -pA2 
(1138887 a.u.) and -pA2∆miR17 (1308562 a.u.) was not statistically significant (p = 
0,2462), when performing an unpaired t test with Welch's correction (Fig. 12).  
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Figure 12 – Fluorescence intensity quantification of the pEGFP MCL1 CDS pA2, and -pA2∆miR17 
constructs. A total of 45 cells in each of the two depicted transfection conditions were quantified, with the 
fluorescence intensity being measured in arbitrary units (a.u). An Unpaired t test with Welch's correction 
statistical analysis was performed, showing that the difference between datasets means was not statistically 
significant (n.s.).  
 
 
In addition, Mcl-1 expressed from the - pA2∆miR17 construct (Fig. 13) presented a 
similar subcellular distribution to the one originated from the - pA2 construct (Fig. 9). 
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Figure 13 – Mcl-1 subcellular localization in HeLa cells, when expressed from the pEGFP MCL1 
pA2∆miR17 construct. On the left column, there are split channels (EGFP: EGFP-fused Mcl-1; Mito. Red: 
mitochondria; Hoechst: nuclei). On the right, there is a merged image of the three channels. The EGFP 
channel fluorescence intensity was maintained according to the parameters set when acquiring images on the 
Sp5 confocal microscope in order to perform correct EGFP quantifications. The fluorescence intensity in this 
image was enhanced using ImageJ to facilitate the visualization of the EGFP-Mcl-1 protein. 
 
 
Genotyping of CRISPR/Cas9-subjected Bulk E6.1 Populations and Isolated Clones Proved 
The Genome Editing to Be Successful 
With the aim of studying separately the function of the MCL1 3’ UTR APA-
derived mRNA isoforms, we used an innovative take on the genome engineering 
CRISPR/Cas9 technology to create stable Jurkat E6.1 cell lines lacking one of the MCL1 
pA signals (pA1 or pA2). In addition, we also applied CRISPR/Cas9 on two other genes 
involved in MCL1 APA: INTS9 and CPSF1.  
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After ten days of puromycin clonal selection of Jurkat E6.1 cells in all eight pLenti 
–sgRNA conditions (Materials and Methods, Lentiviral Transduction), we obtained stably 
dividing cells, which integrated the all-in-one lentiviral vector, containing hSpCas9, the 
chimeric single guide RNA and the puromycin resistance (PuroR) expression cassettes 
(Materials and Methods, Lentiviral Transduction). Therefore, we proceeded to perform the 
first genotyping on those bulk cell populations (Fig. 14a and 14b). This was performed by 
PCR amplification of the genomic regions encompassing the sites of sgRNAs targeting and 
subsequent analysis of the respective electrophoretic profiles in a 1,5% agarose gel, always 
on the background of the non-transduced control E6.1 population (Fig. 14a and 14b, c). 
The CPSF1 KO (Fig. 14a, lane s1), INTS9 KO (Fig. 14a, lane s2), MCL1∆pA1s 
(single sgRNA approach) (Fig. 14a, lane s3) and MCL1∆pA1d (double sgRNA approach) 
[Fig. 14a, lane s4], pLenti – sgRNA conditions (Materials and Methods, “Guide RNAs 
Design Strategy”) presented bands migrating a bit slower than the respective E6.1 control 
bands (Fig. 14a, lanes c). All of the four MCL1∆pA2d pLenti –sgRNA conditions (Fig. 
14b, lanes s1 to s4), on the other hand, presented two bands. In each of these four 
conditions, there was one 671 bp band corresponding to an amplicon size without deletion 
– the wild-type allele, as in the control (Fig. 14b, lane c), in addition to another lower and 
much fainter band with a difference of ~200 bp (Fig. 14b, lanes s1 and s3) and ~300 bp 
(Fig. 14b, lanes s2 and s4), respectively, correspondent to the deletion allele. 
 
 
 
 Figure 14 – Jurkat E6.1 CRISPR/Cas9 bulk populations genotyping. Legend: c- control; MW- molecular 
weight DNA marker; s- sample. a) s1: CPSF1 – upstream – up, and downstream – down, guides; s2: INTS9 – 
up and down guides; s3: MCL1∆pA1s – single guide; s4: MCL1∆pA1d – up and down guides; c – E6.1 b) s1: 
MCL1∆pA2 – up1 and down1 guides; s2: MCL1∆pA2 – up1 and down2 guides; s3: MCL1∆pA2 – up2 and 
down1 guides; s4: MCL1∆pA2 – up2 and down2 guides; c- E6.1. The guide RNAs list is available on table 1 
(forward sequences in capital letters). 
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The subsequent Sanger sequencing of the 8 samples and the associated controls has 
confirmed the occurrence of deletions and their specificity, in seven out of eight pLenti – 
sgRNA conditions, except for MCL1∆pA1s. When the sequences were aligned with the 
control sequences using the Geneious software, in MCL1∆pA2d case (“up1, down1” guide 
pair – Materials and Methods, Guide RNAs Design Strategy), there was a gap delimited by 
the respective pair of the sgRNAs (Fig. 15a), whereas for the CPSF1 KO condition, as 
expected, there was a frameshift being observed in comparison to the E6.1 control and 
reference sequences (Fig. 15b), as well as for INTS9 KO (not shown). 
 
Figure 15 – Sequence alignment of the E6.1 control sequence with the MCL1∆pA2 (a) and CPSF1 KO (b) 
samples, using the Geneious software. a) The sequence of the 3’UTR control (non-transduced) E6.1 cells 
neighbouring region of pA2, top, was aligned with the same region of one of the transduced E6.1 bulk cell 
populations, middle, and the reference sequence (ref.seq.), bottom, in the program Geneious. A large deletion 
including pA2 (light blue arrow) is evident. Guides are depicted by purple boxes (“up1, down1” pair). b) The 
sequence of the E6.1 control sequence was aligned with the CPSF1 KO sample using the Geneious software, 
as in a), with ref.seq. also being depicted, bottom. Instead of a large deletion, there was a frameshift observed 
in the sequence after guide #1.  
 
Given that all pA2 samples presented the deletion and due to their redundancy, 
aliquots of bulk populations from the MCL1∆pA2d “up1, down2” and “up2, down1” guide 
pairs conditions (Materials and Methods, “Guide RNAs Design Strategy) were stored at -
80ºC.  
Thereafter, single-cell sorting of the 5 out of the remaining 6 conditions was 
performed (except for MCL1∆pA1s, due to the lack of pA1 deletion in the bulk population 
genotyping) into 96-well plates – 2 plates per condition. After clonal expansion, 
genotyping was conducted on isolated clones (Fig. 16), with the intention of obtaining 
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homozygous clones in each condition. While CPSF1 KO and the MCL1∆pA1d pLenti – 
sgRNA conditions have shown a distinct electrophoretic profile from that of the control 
(Fig. 16a, the first two lanes c), as it has been previously observed for the bulk populations 
(Fig. 14a), INTS9 KO clones did not display this difference (Fig. 16a, the third lane c).  
As expected, upon subsequent Sanger sequencing, heterozygosity was detected in 
all MCL1∆pA1d and CPSF1 clones, except for the INTS9 KO clones, which presented a 
wild-type genotype. 
Concerning the two MCL1∆pA2d pLenti –sgRNA conditions, we used primers 
located inside the region of the expected deletion, between the two different sgRNAs pairs 
(Fig. 16b, lanes s1 and s2). This approach allowed us to identify the wild-type allele, 
therefore no amplicon was expected after PCR amplification if there was an homozygous 
deletion.   
 
 
 
 Figure 16 – Single-cell sorting –derived clones genotyping. Legend: c- control; MW- molecular weight 
DNA marker; s- sample. a) s1, s2: CPSF1 KO – up and down guides; s3, s4: INTS9 KO – up and down 
guides; s5, s6, s7: MCL1∆pA1d –  up and down guides; b) s1: MCL1∆pA2 up2 and down2 guides; s2: 
MCL1∆pA2 up1 and down1 guides. 
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Discussion 
MCL-1 Alternative 3’UTRs have a function in protein Subcellular Localization  
The subcellular distribution of Mcl-1 was shown to be mainly mitochondrial, in 
accordance with the its anti-apoptotic function at the OMM148–150, as well as with its 
emerging role as a regulator of mitochondrial metabolism and dynamics (fission/fusion) in 
the mitochondrial matrix107,154,155. On the other hand, there were also observations of Mcl-1 
nuclear localization156–159, where Mcl-1 carried on distinct mitochondria-unrelated 
functions. Some of these functions consisted in the regulation of cell cycle progression 
when associated to Cdk1157, or with the mesenchymal-epithelial transition when physically 
interacting with STAT3159. The latter actually leads to an increased rate of apoptosis, as 
opposed to the conventional anti-apoptotic function of Mcl-1 full-length protein isoform119.  
It has been previously described that the Mcl-1 mitochondrial localization is greatly 
enhanced by its N-terminus, namely by the first 79 aa featuring a putative mitochondria-
targeting sequence150, as well as relying heavily on the presence of the C-terminal 
Transmembrane Domain, which allows anchoring to the OMM150,199. In accordance, Mcl-
1S AS isoform, which lacks the C-terminal Transmembrane Domain is primarily 
cytosolic133.  Moreover, the Mcl-1 subcellular localization also relies on its recruitment by 
protein interaction partners (PIPs), namely the Mcl-1-Noxa complex mitochondrial co-
localization151 and Mcl-1 recruitment to the nucleus by the IEX-1 factor158. However, the 
involvement of non-coding sequences in Mcl-1 localization has not been investigated yet. 
Our group has previously unveiled the expression of two APA-derived mRNA isoforms in 
T cells, varying only in the length of their 3’ UTRs – the short isoform, which uses the 
proximal pA signal (pA1) and has a 1418 nt long 3’ UTR, and the long isoform, which 
uses the distal pA (pA2) and has a 2828 nt long 3’ UTR197.  This extensive 3’ UTR harbors 
various potential and identified RBP binding motifs135–138, apart from miRNAs binding 
sites139, allowing for a complex regulation of MCL1 transcripts fate, such as mRNA 
stability and translation.   
In addition to these two aspects of modulation of gene expression, the role of the 3’ 
UTR in protein function in subcellular localization has been previously demonstrated by 
Mayr and Berkovits for CD47, who presented the 3’ UTR-dependent protein localization 
(UDPL) model, using a range of human cell lines52. Their work uncovered that HuR only 
binds to the long CD47 3’ UTR mRNA isoform, where it serves as an RBP adaptor for 
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SET, the latter being transferred during translation from the 3’ UTR onto the CD47 nascent 
cytoplasmic domains, thereupon recruiting RAC1 (Fig. 2). Thereafter, active RAC1 
translocates the whole protein complex to the plasma membrane (PM), where high levels 
of CD47 are needed to fully protect cells from phagocytosis52. 
On the other hand, the short CD47 3’ UTR APA-derived mRNA isoform, which 
cannot bind by HuR, is translated into a protein that while not being targeted to the PM, 
accounts for CD47 cytoplasmic localization. However, unlike PM CD47, cytoplasmic 
CD47 is pro-apoptotic, restoring apoptosis in gamma-irradiated CD47-defficient Jurkat 
cells (JinB8), upon exogenous expression from the short CD47 3’ UTR APA-derived 
mRNA isoform, but not from the long52.  Thus, thanks to the regulatory landscape 
provided by the 3’ UTR, both a differential localization and an independent expression of 
two proteins is being achieved, which while bearing the same aminoacid sequence, 
perform two distinct functions. 
Inspired by the elegant model proposed by Mayr and Berkovits52, we sought to 
discover whether the two MCL1 transcript isoforms with alternative 3’ UTRs, may mediate 
a similar sort of regulation, namely protein partners recruitment, and thus, target the Mcl-1 
protein to different subcellular compartments (mitochondria, cytosol, nucleus). In order to 
do so, we performed overexpression and localization assays in HeLa cells using the pEGFP 
MCL1 CDS pA1 and the pEGFP MCL1 CDS pA2 constructs. Indeed, like Mayr and 
Berkovits52, we observed a differential Mcl-1 subcellular localization dependent on the 
3’UTR: predominantly mitochondrial for the MCL1 CDS pA1, although with very low 
cytoplasmic and nuclear expression (Fig. 8), and ubiquitous for MCL1 CDS pA2 (Fig. 9), 
encouraging us to further explore the possibility of Mcl-1 regulation according to the 
UDPL model. Given that the MCL1 CDS pA1 mitochondrial localization was consistent 
with the previous reports on Mcl-1 localization using expression constructs containing only 
the coding sequence149–151, we deemed that the pA1 3’ UTR was not essential for Mcl-1 
mitochondrial targeting. However, our first hint was that the pA2 3’ UTR could specify for 
alternative Mcl-1 localizations, other than mitochondrial, namely: nucleus and cytoplasm, 
thereby dissolving the mitochondria-shifted protein accumulation. According to the 
bioinformatics analysis using the RBPmap Version 1.1 (http://rbpmap.technion.ac.il/), 
there are five putative RBP binding motifs in the pA2 3’ UTR sequence that do not overlap 
with pA1 3’ UTR. These are binding motifs for FXR1 (fragile X mental retardation 
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syndrome-related protein 1), FXR2, PCBP2 (Poly(rC)-binding protein 2), RBM3 (RNA-
binding protein 3) and SFPQ (splicing factor, proline- and glutamine-rich), whose RBPs 
expression in T cells was confirmed using the EMBL-EBI Expression Atlas. However, 
when assessing the five RBPs’ gene ontology there was no hit for a role in protein 
localization, but rather for regulation of protein translation rate and stability, such as for 
FXR1200 and RBM3201. Still, these RBPs may themselves be responsible for modulating 
MCL1 CDS pA2-derived Mcl-1 localization, or may recruit protein effectors, acting as 
RBP adaptors53. However, given that the 3’ UTR region harbors numerous repeats and 
stretches of identical nucleotides (A/U), it may also form secondary structures that may 
affect the accessibility of certain miRNAs202 or RBPs binding sites53,54,203. Thus, when 
looking into candidate proteins involved in Mcl-1 UDPL regulation, in fact, one should 
consider the whole sequence and not only the non-overlapping part. 
 
Still in compliance with the Mayr and Berkovits’ UDPL model hypothesis52, the 
differential protein localization could stem from a difference in protein import into the 
mitochondria. Slower mitochondrial import has already been reported for exogenously 
expressed Mcl-1 with a truncated N-terminus150,199. Even though the two Mcl-1 proteins 
(MCL1 CDS pA1 and pA2- derived) bear an identical amino acid sequence, only differing 
in their 3’ UTRs, they still may engage with different protein partners recruited by their 
alternative 3’ UTRs52,53. Thus, one type of PPI could target the Mcl-1 protein complex 
more efficiently to the mitochondria, and/or allow it to be more readily imported. 
Furthermore, the previously reported mitochondria co-localization event promoted by the 
establishment of the Noxa/ PMA1P - Mcl-1 PPI151 could hypothetically be the one 
modulated by UDPL. Even though the protein expressed from the MCL1 CDS still engages 
with Noxa151 and is thus targeted and imported into mitochondria, the UDPL model can 
potentially speed up this interaction.  
Another possible protein interactors involved in mediating the import process are 
heat shock proteins (HSPs), some of which were recently unveiled as non-conventional 
RBPs, capable of binding RNA through  their intrinsically disordered regions (IDRs)54. 
There are two chaperone systems involved in mitochondrial transport: Hsp90 (Heat shock 
protein 90)/p23 and Hsc70 (Heat shock cognate 70 kDa)/Hsp40204. In both systems, heat 
shock proteins bind newly translated mitochondria-targeted protein precursors, in the 
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cytosol, and escort them to the mitochondria in a translocation-competent, unfolded, 
state204. There, they facilitate mitochondrial entry upon promoting mitochondria-targeted 
protein interaction with the TOM (translocase of the outer membrane) receptors204, with 
Mcl-1 having been shown to interact with the mitochondrial import receptor Tom70, 
through an N-terminus internal motif199. According to Biogrid 3.4 site 
(https://thebiogrid.org), Mcl-1 directly interacts with three HSPs: HSP1A1, HSPA4 and 
HSPA8, with HSP1A1, in particular, being recently identified as an unconventional RBP54. 
Thus, they could interact with Mcl-1 through their recruitment to the 3’ UTR of MCL1 
transcripts, which could be preferential of the short pA1 isoform. Alternatively, HSPs 
could be recruited by other RBP adaptors to the nascent protein, modulating its 
downstream fate.  
 
In accordance with the previous finding of our group showing by reporter assays 
that the pA1 isoform produces more protein, the pEGFP MCL1 CDS pA1 construct gave 
rise to a significantly higher level of EGFP fluorescence intensity (Fig. 11), with pA1 
producing ~3-fold more protein than MCL1 CDS pA2. This more efficient protein 
production from the short isoform was most likely related to the evasion of cytoplasmic 
regulation by miRNAs, different kinds of RBPs and through destabilizing cis-elements 
present and/or only made available in the long 3’ UTR. Thus, we sought to find whether 
miR-17 was responsible for this downregulation of Mcl-1 expression in MCL1 CDS pA2. 
However, the MCL1 CDS pA2∆miR17 construct, with its mutated miR17 binding site197,  
located inside the non-overlapping region of the pA2 3’ UTR, did not render a significant 
enhancement of Mcl-1 expression when compared to the pEGFP MCL1 CDS pA2 
construct (Fig. 12). That finding only proved the complexity of cell regulatory processes, 
with multiple cytosolic events accounting for negative modulation of mRNA expression.  
 
Moreover, overexpression of MCL1 CDS pA1 seemed to affect mitochondria 
morphology, namely shifting it from a ring appearance to a more agglomerated phenotype 
(Fig. 10b). This was opposed to MCL1 CDS pA2, but in compliance with the previous 
studies linking Mcl-1 with modulation of mitochondria morphology. Thus, knockdown of 
Mcl-1 was recently reported to promote mitochondria organelles fusion and elongation in 
human Embryonic Stem Cells (hESCs)155. Mcl-1 high expression levels, on the other hand, 
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were linked with a fragmented mitochondrial network (fission) in induced Pluripotent 
Stem Cells (iPSCs), in comparison to the parental fibroblasts155. Taking those findings into 
account, in the future, it would be interesting to investigate a possible role for MCL1 3’ 
UTR in shaping mitochondria morphology.  
Overall, the EGFP reporter localization studies revealed that we are currently only 
in the beginning of unraveling the complex regulation to which MCL1 is subjected. 
However, we are now confident that MCL1 3’ UTR regulatory potential extends beyond 
the regulation of its transcript translation efficiency, affecting also the protein fate, 
including subcellular localization. 
 
CRISPR/Cas9 Genome Editing Of Jurkat E6.1 Cells 
Although the GFP reporter gene assay provides one of the most expeditious ways 
to tag and explore the localization profile of one’s protein of interest (POI), it has its 
intrinsic caveats. For instance, the expression of exogenous protein at non-physiological 
levels may disturb cellular functions, altering the cell phenotype205,206. In addition, 
overexpression can alter trafficking or post-translational modification of the protein N-
terminally fused with a 27 kDa GFP, with a tag being capable of interfering with protein 
folding and establishment of protein–protein interactions205. Thus, data gathered from GFP 
reporter gene assays may differ from what can be observed in native conditions. 
 Thus, we sought to carry on our research in a clean, unbiased and physiological 
framework, by applying the CRISPR/Cas9 genome editing tool on Jurkat E6.1 T cells, with 
the aim of dissecting separately the in vivo functions of the MCL1 pA1 (~1,5 kb) and pA2 
(~2,8 kb) alternative 3’ UTRs, in their physiological context. In addition, we asked 
whether the knock-out of two relevant genes involved in RNA processing, INTS9 and 
CPSF1, would impact MCL1 polyadenylation and/or alternative polyadenylation outcome, 
as well as cell viability.  .  
The gene delivery systems can be either viral- (cell transduction) or non-viral-
mediated (cell transfection). Although advances and optimization efforts in cell 
transfection have brought promising results in recent years, such as in electroporation207–
209, DNA transfection may limit the use of multiplex genome engineering due to the 
associated toxicity, as described for primary T cells upon DNA electroporation210. Viral-
mediated delivery does still present the higher efficiency211, despite the fact that the 
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integration of a viral gene into a host cell genome poses serious safety concerns212,213 as 
well as experimental drawbacks (e.g. the risk of insertional mutagenesis213). Given that 
Jurkat E6.1 cells, have been proven as hard-to-transfect208,214, and the advantages of viral-
mediated delivery, we chose lentiviral transduction, using the lentiCRISPR v2 vector, to 
deliver our all-in-one pLenti –sgRNA constructs (gRNAs listed in table 1) into E6.1 cells. 
 
The occurrence of E6.1 genome editing in seven out of eight pLenti –sgRNA 
conditions in bulk cell populations, corroborated by PCR (Fig. 14a and 14b) and Sanger 
sequencing (Fig. 15a and 15b) proved the efficiency of our lentiviral transduction. The 
observed mixed populations of wild type alleles and the ones harboring indels or deletions 
(Fig. 14 and 15) suggested three possible outcomes of our sgRNAs genome targeting 
approaches, namely: the existence of wild type cells and the ones with the two of their 
respective alleles being mutated, the existence of heterozygous cells and, much more 
probably, the overlapping of the two scenarios. The latter hypothesis was confirmed upon 
obtaining isolated clonal populations for each condition, and genotyping, which rendered 
heterozygous and wild-type genotypes (Fig. 16a and 16b).  
Overall, we obtained only a few clones in each pLenti – sgRNA condition (Fig. 16) 
upon single-cell sorting into 96-well cell-culture plates, which was not surprising. This was 
because, on one hand, the scale of our single-cell sorting experiment (two plates per 
condition) was small and, on the other hand, because the Jurkat cells, including E6.1, 
respond negatively to low density/isolation, appearing to need growth factors produced by 
neighbor cells.  
Nevertheless, the majority of our clones presented a deletion, but all of those were 
heterozygous. This could be because the Cas9 endonuclease mediated genome editing is a 
stochastic event, whose outcome is therefore unpredictable215, in spite the good efficiency 
(score) of the designed sgRNAs (ranging from 70 in MCL1∆pA2d to 96 in CPSF1 KO) 
[table. 1]. Even though heterozygosity was achieved for our clones, it was our aim to attain 
homozygosity to allow functional assays to be performed.  
A large number of APA factors are required for appropriate polyadenylation 
processing to occur, including cleavage and polyadenylation specificity factor (CPSF), 
cleavage stimulation factor (CSTF) and cleavage factor I and II (CFI and CFII) 
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complexes,  the poly(A) polymerase, as well as a panoply of other associated 
factors43,216.  
Some of these basal polyadenylation factors have already been described to have 
roles in APA as well. CSTF2/CstF64, which is an essential polyadenylation factor 
binding the GU-rich DSEs10, was demonstrated to act as an important regulator of 3′ UTR 
shortening in B cell differentiation60 and across several cancer types [e.g. bladder 
urothelial carcinoma (BLCA), head and neck squamous cell carcinoma (LUSC)]217. CstF-
64 and CFI(m) proteins have much higher positional specificity around the PAS most 
frequently used than CPSF 218. However, the latter plays a major role in recruiting CstF-64 
to RNAs219. 
The CPSF1/CPSF160 factor, while not being shown to be involved in APA so far, 
has already been described as an important regulator of alternative splicing, either 
inhibiting alternative exon inclusion, such as in the Interleukin 7 receptor – IL7R19,  in T 
cells19, or promoting it, as shown for the Androgen Receptor – AR21, in Castration 
Resistant Prostate Cancer (CRPC) cells21 and also at the genome wide level 220. Being 
mindful of the recent study made by Sun and colleagues44, which uncovered that CPSF1 
functions as a recruitment platform for CPSF-30 and WDR33 and primes them for high-
affinity binding to AAUAAA, allows revisiting the earlier established roles for CPSF1. 
The latter makes it clear that while CPSF1 does not interact with pre-mRNA directly, it is 
still crucial for the assembly of the CPSF complex on internal polyadenylation signals, and 
therefore its interplaying with the spliceosome machinery.  
With CPSF1 being a basal polyadenylation factor, and armed with knowledge 
available to date concerning CPSF1 regulatory function, we sought to pursue its 
possible implication in MCL1 APA outcome. In order to achieve this, we planned a two-
allele KO for its gene in E6.1 cells, through lentiviral transduction of all -in-one pLenti –
sgRNA constructs.  
The fact that in the beginning of the puromycin selection, there were high mortality 
levels across all of the eight CRISPR/Cas9 conditions (Materials and Methods, Lentiviral 
Transduction) was not surprising given the incomplete efficiency of the transduction 
approach, with only cells which incorporated the lentiCRISPR v2 constructs expressing the 
PuroR gene and hence surviving. However, the mortality was notoriously higher in the 
beginning for the CPSF1 KO condition, having stabilized only after a week of puromycin 
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selection. This observation suggests that the homozygous CPSF1 knockout was lethal for 
the cells, highlighting even on the background of the overall cell mortality levels due to the 
Puro-induced cell death of the non-transduced part of the bulk population, in comparison to 
other conditions. The following stabilization was probably due to the survival and 
proliferation of heterozygous clones. In fact, we have detected those upon bulk population 
and single-cell sorting isolated clones genotyping (Fig. 14a and 16a, respectively).  
 
Integrator (INT) is a transcriptional regulatory complex associated with the CTD of 
the RNAPII221, being endowed with a core catalytic RNA endonuclease activity which is 
required for the 3’ end processing of both uridine-rich small nuclear RNAs (UsnRNAs)221 
and of transcripts derived from distal regulatory elements (enhancers) – enhancer RNAs 
(eRNAs)222, the latter being involved in spatiotemporal regulation of gene expression in 
metazoan species223–226. Very recently, it was discovered that the Integrator most critical 
module, containing the endonuclease activity, was composed of the Integrator subunit 4 
(INTS4) interacting with the INTS9/11 (endonuclease)227. 
By cleaving its target transcripts, Integrator thus promotes their processing to a 
mature form, which is intimately coupled with transcriptional termination221. In addition, it 
was revealed that the Integrator complex plays a termination function at diverse classes of 
target genes, including replication-dependent histone mRNAs and genes with 
polyadenylated transcripts198. Concerning the latter, Integrator binds the promoter proximal 
sites, which positively regulates gene expression. Furthermore, Integrator plays a critical 
role in both initiation and the release of paused RNAPII at immediate early genes (IEGs) 
following transcriptional activation by epidermal growth factor (EGF) in human cells, 
recruiting the super elongation complex (SEC) and thus allowing  productive transcription 
elongation228. The surprising spectrum of Integrator functions in gene expression has been 
reviewed in 2015229.  
Given that our group preliminary findings have suggested that INTS9 was 
implicated in MCL1 APA in T cells, with its knockdown affecting the expression of the 
MCL1 pA2 isoform,we sought to pursue this new possible role for INTS9, having planned 
a two-allele KO for its gene in E6.1 cells.  
In the beginning of puromycin selection, the mortality levels for INTS9 KO 
condition were not as striking as those for CPSF1, being similar to the MCL1∆pA1s/ pA1d 
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and MCL1∆pA2d conditions. This observation was suggestive of a non-essential role of 
INTS9 in cell survival, given that there is no INTS9 function redundancy with other 
proteins (e.g. other integrator subunits). Although we have found heterozygous clones in 
the bulk population upon genotyping, no homozygous, nor heterozygous clones have so far 
been obtained for the INTS9 KO condition due to the low numbers of clones having 
survived the single-cell sorting. 
 
Although it is difficult to apply CRISPR/Cas9 in the 3’ UTR because of its high A/ 
T content due to various AU-rich elements230, while the PAM sequence trinucleotide needs 
to have at least two “G”,  this technology has been previously successfully applied to target 
3’ UTRs. For instance, Song and colleagues performed a deletion of the tyrosinase (Tyr) 3’ 
UTR in rabbit zygotes231 and Zhao and colleagues deleted sequences corresponding to 3’ 
UTRs of nine chemokines in Human bronchial epithelial BEAS-2B.tTA cells232, with a 
dual sgRNA approach being applied in both cases. 
 
However, to our knowledge, genome editing has not been applied so far to 
exclusively delete pA signals in the 3’ UTR. Therefore, we decided to adopt an innovative 
take on the CRISPR/Cas9 technology. Our attempts to delete a large genomic region 
encompassing the pA2 signal (200-300 bp), as well as a smaller region including the pA1 
signal (~70 nt), were similar to the previous approaches of Song and colleagues231 and 
Zhao and colleagues232, relying on double sgRNAs targeting. However, the single sgRNA 
targeting of a sequence near the pA1, (with a predicted cleavage site being only 5 nt apart 
from the hexamer), relied on the NHEJ pathway to introduce mutations in the pA1 signal 
sequence, being thus an unprecedented approach. Our intention of deleting a small 
sequence including the pA1 signal was dictated by the fact that we could not delete an area 
that was too large, as it may contain regulatory sequences needed for the pA2 mRNA 
isoform.  
We screened for the presence of a wild-type allele in MCL1∆pA2d because we 
were primarily interested in obtaining homozygous clones and because we had primers 
available matching the region delimited by the sgRNA pairs. This approach has proven 
efficient, allowing us to rule out the two MCL1∆pA2d clones straight away as immediate 
candidates for the functional assays.  
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Thus, our CRISPR/ Cas9 approaches are yet to realize their full potential, which 
will only be possible after obtaining the homozygous isolated clones, on which we will 
perform the functional assays. 
In conclusion, the successful establishment in our lab of the complex protocol 
involved in CRISPR/Cas9 mediated genome editing, ranging from the in silico gRNAs 
design to lentiviral constructs assembly and lentiviral transduction of difficult-to-transfect 
cells is a big achievement. 
 
Future Perspectives 
Mechanisms Of Mcl-1 Subcellular Localization  
The next step in unraveling the regulatory landscape of the two MCL1 3 UTR 
APA-derived mRNA isoforms would be to look into the RBPs that bind their alternative 3’ 
ends. Firstly, it would be interesting to knock down some of the RBPSs identified in the 
RBPmap binding the pA2-isoform specific 3’ UTR part of MCL1 (see section above), and 
see whether it would affect Mcl-1 localization and/or translation efficiency.  
In parallel, given that the mass spectrometry (MS) technology is not feasible to 
apply to study proteins bound to large RNA sequences, we would need to create various 
alternative large deletions in the 3’ UTR and then perform mass spectrometry to uncover 
the bound RBPs. Afterwards, it would be possible to perform a UV cross-linking and 
immunoprecipitation of the MCL1 3’ UTR-derived ribonucleoparticle (CLIP) using 
antibodies against the RBPs identified by MS, thus confirming their binding status. 
 
 
CRISPR/Cas9: The In Vivo Function Of MCL-1 Alternative 3’UTRs And Identification Of 
MCL1 APA Regulators  
In our future work, we will proceed to scale up the single-cell sorting experiment, 
using approximately ten 96-well plates per each CRISPR/Cas9 condition. Then, we will 
genotype the isolated clones, screening for homozygous ones. In parallel, we will perform 
a second round of lentiviral transduction with the pLenti – sgRNA constructs-containing 
lentiviruses on the already obtained heterozygous clones, in case the homozygosity will 
continue failing to be achieved upon scaling up the experiment.  
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Finally, we will perform functional assays on homozygous clones for INTS9 and 
CPSF1 knockouts and for MCL1∆pA1 and MCL1∆pA2, such as localization of 
endogenous Mcl-1, which would be a more physiological and thus biologically significant 
approach in comparison to reporter/overexpression assays conducted with cell transfection. 
In addition, we will assess the levels of apoptosis in our engineered E6.1 populations 
(annexinV/propidium iodide assays). 
 
These experiments will further promote our understanding of the MCL1 3’ UTR-
APA-derived mRNA isoforms regulation, by providing us with opportunities to delve 
deeper into its subjacent mechanisms and molecular players. 
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